Immunic, Inc. Stock price
Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 SBC | in % Revenue
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to revenue.
🧮 How is it calculated?
SBC as % of Revenue = (SBC ÷ Revenue) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of revenue shows how heavily a company relies on equity-based compensation and how significant this form of compensation is relative to the size of the business.
🎯 What does this mean for investors?
- A lower figure is generally positive: Stock-based compensation is relatively small compared with the company's revenue.
- A high figure can indicate greater reliance on stock-based compensation and a higher potential risk of dilution. However, it is also important to consider whether the company offsets dilution through share buybacks.
- The trend over time should also be considered. A high but declining percentage presents a different picture from a persistently high or increasing percentage.
- A single-digit SBC-to-revenue ratio is not unusual among many growth-oriented and technology companies.
📘 SBC as % of FCF
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to free cash flow (FCF).
🧮 How is it calculated?
SBC as % of FCF = (SBC ÷ Free Cash Flow) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of free cash flow shows how significant SBC is relative to the cash generated by the company. Since SBC is non-cash compensation, it is typically not deducted as a cash outflow when calculating FCF.
🎯 What does this mean for investors?
- A lower value is generally favorable. Stock-based compensation is relatively small compared with the company's cash generation.
- A high value means that SBC represents a significant portion of the company's reported free cash flow, even though SBC itself is non-cash.
- The higher the value, the more significant SBC can be as an economic cost to shareholders, particularly when it results in share dilution.
📘 SBC Growth 1Y
📈 What is it?
SBC Growth 1Y shows how much a company's stock-based compensation has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
SBC Growth shows whether stock-based compensation is becoming more or less significant for shareholders. If SBC increases significantly, it can lead to greater shareholder dilution over time. At the same time, SBC is a non-cash expense that reduces earnings on the income statement but is added back in the cash flow statement.
🧮 Calculation
🎯 What does this mean for investors?
- A high positive value is generally negative, as rising SBC can increase the burden on shareholders, particularly through potential dilution.
- What matters is whether the development of SBC is sustainable over the long term. Some level of SBC is common among many growth and technology companies.
📘 Share Count Growth 1Y
📈 What is it?
Share Count Growth 1Y shows how much the number of shares outstanding has increased or decreased over a one-year period.
🧮 How is it calculated?
🏛️ Why is it important?
The number of shares determines how many shares the company's earnings and assets are distributed across. If the share count decreases, existing shareholders' relative ownership increases. If it increases, existing shareholders are diluted. The metric therefore makes dilution and share buybacks directly visible.
🧮 Calculation
🎯 What does this mean for investors?
- A negative value is generally positive, as the number of shares outstanding is decreasing.
- A positive value indicates dilution of existing shareholders.
- A declining share count is not automatically positive: It also matters at what price the shares are repurchased and how the buybacks are financed.
📘 Shareholder Yield
📈 What is it?
Shareholder Yield measures how much capital a company returns to shareholders through dividends and share buybacks, relative to its market capitalization. It goes beyond dividend yield by also including share buybacks.
🧮 How is it calculated?
🏛️ Why is it important?
Dividend yield only tells part of the story. When a company buys back shares and the share count falls, each existing shareholder owns a larger part of the company. When the share count rises, for example through stock-based compensation or new share issuance, existing shareholders are diluted. Shareholder Yield combines both into one metric.
🧮 Calculation
🎯 What does this mean for investors?
- A higher Shareholder Yield indicates more capital being returned to shareholders.
- A negative value means the company issued more new shares than its dividends and buybacks make up for.
- Share buybacks are most beneficial when shares are repurchased at attractive valuations.
- Investors should also consider whether dividends and buybacks are sustainable over time.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🧮 Calculation
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
Immunic, Inc. Stock Analysis
Analyst Opinions
19 Analysts have issued a Immunic, Inc. forecast:
Analyst Opinions
19 Analysts have issued a Immunic, Inc. forecast:
Immunic, Inc. Events
Past Events
|
NOV
13
Q3 2026 Earnings Call
6 days ago
|
|
NOV
5
Special Call - Immunic, Inc.
14 days ago
|
|
SEP
9
Special Call - Immunic, Inc.
2 months ago
|
StocksGuide Free
Immunic, Inc. — Special Call - Immunic, Inc.
1. Management Discussion
Hello, and welcome to Immunic virtual R&D Day focusing on our progressive MS development program with our investigational asset, Vidofludimus calcium. I would like to welcome everyone attending our event today.
My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic, and I will be the moderator for today's webinar. A few organizational remarks. [Operator Instructions] This event is being recorded. [Operator Instructions]. As always, before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.
Please note that these forward-looking statements reflect the Immunic's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.
Let's move on to today's actual agenda. I'm super excited that 2 internationally renowned experts will be speaking on the call today, Dr. Jiwon Oh from the University of Toronto and Dr. Maria Pia Sormani from the University of Gina Italy. Moreover, we will have our Immunic management team presenting, including Eric Langren, CEO; Dr. Hella Kohlhof, CSO; Dr. Mike Panzara, CMO; and Jason Tardio, President and COO. During today's event, the group will discuss the key unmet needs and progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with new degeneration and MS progression.
In Immunic management will highlight the potential expansion opportunity for vidofludimus Calum and progressive MS, including the clinical and scientific rationale supporting the initiation of a Phase III progressive MS trial.
With this, I would like to hand over to our CEO, Eric Lundgren, to kick things off. Eric?
Great. Thank you, Jessica, and thank you, everyone, who's joining us live and/or anyone who aches the recording after the fact. Really appreciate your interest in in Immunic and vidofludimus calcium and in our very important efforts in progressive MS. So next slide, please, Jessica.
I'll be quick. I just want to set a little bit of the context here. It's an extraordinarily exciting time at Immunic. We're really in a pivot, so pivoting towards a fully integrated commercial company with a real laser focus on multiple sclerosis. And while we're going to spend the vast majority of today talking about our efforts in Progressive MS, which I think, represents the greatest unmet need in multiple sclerosis.
It would be remiss of me to not mention that we also have a very near-term catalyst in relapsing MS. And so we have 2 Phase III studies, the ENSURE-1 and ENSURE-2 studies that are reading out in December. Everything is on track for that. And we look at that as a near-term value inflection point for the company.
If those studies are successful, allow us to submit an NDA next year and reach the market in 2028 with a relapsing indication. And that will allow us to really establish our presence commercially. Further advance and mature the company and ultimately get to profitability so that we can support the next value horizon, which is truly defined by the topic of today, which is progressive MS.
This is, as I said already, arguably the largest unmet need in MS today, and it represents progress in this space represents tremendous value for the MS community, most importantly, for people living with MS and of course, for the company as well.
So truly, truly excited about the moment that we're in here sitting on the cusp of data for our relapsing indications and simultaneously preparing for and initiating our studies our further study, Phase III study in progressive MS. It really is an example of what we're trying to build here, which is a leading organization focused on MS and people living with the disease, both in terms of how we're building ourselves.
But also, I think you'll see in the presentations today, a reflection of us really starting with the patient and listening to what they value, what they struggle with and ultimately what would be meaningful for advancing and improving their lives.
Next slide, please, Jessica. So as you can see here, we have a lot going on, but in green, we're going to be talking at the bottom of the slide, you see our Phase I progressive MS study called the CALLIPER study. This study has been fully read out. And Dr. Mike Panzara will walk through some of the detailed findings of that study that enrich our hypothesis and thesis around our ability to really meaningfully move the needle in progressive MS.
And that Phase II data is a big part of the basis of that confidence as we move into, as I said, a Phase III study in progressive MS. That study is in preparation and being initiated. Now with a plan for the first patients to be enrolled in the first half of next year.
Next slide, please. So last setup here, as I walked through right now, it's about building the foundation for a commercial organization focused, laser-focused on MS. That work is happening as we speak. In this middle period, following an FDA approval based on the insured data set in relapsing disease, we start to scale, we really establish ourselves in the MS community.
We're generating cash and getting to sustainability from an operating environment and balance sheet environment in that middle period. All setting up for and in preparation for becoming truly a global leader in MS on the back of both the ENSURE data, but also the progressive MS data that we'll talk about here.
So as I said, extraordinarily exciting time here at the company we're really -- we feel so privileged to have an asset like this and an opportunity like this to lean into advance care across the full spectrum of multiple sclerosis. So with that, let's get into the topic of the day.
It is my distinct pleasure to have the opportunity to introduce Dr. Jiwon Oh. Dr. Oh is a staff neurologist scientist and Medical Director of the Barlow MS program at St. Michael's Hospital at the University of Toronto. Her research focuses on developing advanced MRI techniques for the use in clinical settings, the development of large data sets and of course, her work as a clinical trial list.
She leads the MRI research program at St. Michaels Hospital and is the principal investigator on numerous local and international multicenter collaborative studies. Dr. Oh is deeply committed to caring for people with MS, educating future generations of clinicians and scientists and contributing to scientific developments that will drive the MS field forward.
So with that, it is my distinct pleasure to welcome Dr. Jiwon Oh.
Thank you, Eric, and hello, everybody. I am going to in the next just set the stage for much of the discussion today and talk about what the greatest unmet needs are in MS and how important progression is throughout the entire disease course. So I'd say in the last 10, 15 years, what is becoming abundantly clear in the MS field to MS neurologists to people living with MS as well as scientists is that MS really is a disease spectrum.
And we used to think that relapsing disease was really what happened at the beginning of disease in almost everybody. There was really very little progression until much later stages of disease or in people who are initially diagnosed with primary progressive MS, but in part because of the successes of our treatment of relapsing disease biology, we're recognizing more and more that MS really is a disease spectrum.
And there is this huge overlap of both relapsing and progressive disease biologies from the very beginning of disease until the very end of disease. And because of this recognition, international Think Tank groups like the International Clinical Trials Committee is publishing papers like this, which suggests we really need a new mechanism-driven framework to describe the entire MS disease course.
So probably the best pieces of evidence that illustrate this concept of MS as a disease spectrum and that both relapsing and progressive disease biologies are at play across the entire disease course -- is this publication of the first systematic description of progression that is independent of relapsing activity or PIRA or PIRA, as we like to call it, -- and this was first done back in 2020 by Ludwig Capitals and colleagues and this was actually a post-hoc analysis of the pivotal Phase III clinical trials that looked at ocrelizumab versus interferon beta 1a in people with relapsing MS.
So like most contemporary relapsing MS clinical trial population, this was a relapsing MS population that was very early in the disease course. So within a few years of diagnosis. And so when these investigators looked at this concept of PIRA, which was essentially progression or disability worsening happening well outside of the context of any clinical relapse. They were actually surprised to see that despite the fact that in our heads, we always think that progression really does not happen in people with relapsing MS.
They found that actually PIRA happens very commonly in people with relapsing MS very early in the disease course. And when you look at the disability worsening events in these clinical trials that happened, the vast majority, so nearly 80% to 90% of them were due to PIRA.
So this was a bit of a moment in the field when we recognize that -- you know what, progression that happens outside of the context of relapses is not something that only happens in progressive forms of MS or in the later stages of disease, it absolutely happens and happens very frequently from the very beginning of the disease.
In addition, when you look at contemporary MS clinical trials that looked at purely progressive forms of disease. And again, we think based on that prior framework, that in these people, there should be very little evidence of relapsing disease activity.
What we see, say, in Oratorio, that looked at primary progressive MS and ocrelizumab expand that looked at SPMS and siponimod and Hercules that recently looked at non-relapsing secondary progressive MS and tolebrutinib, when you look for gadolinium-enhancing lesions, which we think is the MRI equivalent of relapsing disease activity, you very clearly see that even when you're trying to look at purely progressive populations, you have actually a substantial portion of people that even at the beginning of the trial show evidence of relapsing disease activity based on MRI features.
So all of this shows us and clearly illustrates that MS is a disease spectrum and that both relapsing and progressive disease biologies happen across the entire disease spectrum. So you might say then what does this mean for the field? Well, we're at somewhat of a crossroad you might say, because this whole framework that we use to describe MS and to recruit for clinical trials is clearly problematic and we're recognizing this again because in a way we've been so successful with treatments that can really get rid of any evidence of relapsing disease activity.
And it's clear that we need to figure out a better framework to move forward. And this is exactly where that international clinical trials Committee is really trying to play a role in driving this forward.
And very recently, the Clinical Trials Committee published this paper talking about a road map of how we might transition from that old framework that we've used until now towards a more biologically informed description of MS disease course, which is very clearly needed in the field. first, for drug development because in clinical trials, we need to figure out how to do these trials better and that we're not relying on that prior framework and in clinical practice because there probably are emerging treatments in the next number of years that address aspects of progressive disease biology, we absolutely need to figure out how to describe MS more accurately.
So in that paper that was just published, there is a whole bunch of statements indicating what we might do as a field. But the take-home points really are that -- we can't describe MS based on clinical features alone. It's really clear that a multimodal assessment of MS is needed and that this needs to be done across the MS disease course.
So we can't just say someone has relapsing MS based on the fact that they have clinical relapses we need pair of clinical evidence of relaxing disease as well, whether that's using MRI or blood biomarkers and we need to take into account functional status and modifiers. And as you can see from the figure on the right, this is again because this has huge implications, not just for the science in MS, but also for drug development as well as clinical practice.
So you might ask then other than that, what is the greatest unmet need in MS. So clearly, we need a better framework as to how to describe. But truly, from a clinical perspective, the greatest unmet need in clinical practice are treatments for progression that can definitively alter the trajectory of disease.
So we have currently 2 treatments actually that are approved for progressive MS, ocrelizumab and siponimod, but we know in the field that these treatments are modestly beneficial at best. And very importantly, they actually do not target disease processes underlying progression that's independent of relapsing activity.
And I'm displaying here again, that study, that first systematically described PIRA, that study not only illustrates this concept of MS as a disease spectrum, but very clearly shows us that even when you use our highest efficacy therapies, progression still happens and the progression that happens is related to PIRA. And so it's very clear that this is truly the greatest unmet need in clinical practice.
So you might then ask, why is it so difficult for the field to address this unmet need? Why has it taken so long, why do you have 20-plus treatments that can address relapsing disease biology, but very few, if any, that actually definitively can address progression independent of relapsing activity. And this is because the mechanisms underlying progressive disease biology are really complicated.
And this is an illustration of the various different pathophysiologic processes that we understand are relevant, but there probably are many different disease processes that we don't understand as well. And so this is an area in the scientific field that is being intensely studied.
In addition, another major reason why we have not been able to definitively address this unmet need is because progression is actually very difficult to measure accurately, particularly in a complex chronic neurologic disease like MS that last decades, if not a lifetime. And this is a huge problem that we have because in clinical trials, we're still focusing on some of these clinical measures that we know are problematic, like the EDSS, which is a scale measuring global neurologic disability, but we know that it is both insensitive to subtle neurological change, and it's insensitive to aspects of MS that are most important to patients, including cognition and fatigue.
And so the field has moved towards composite endpoints -- but they're still problematic as recent clinical trials have illustrated where we were including things like 25-foot time walk in the 9-hole peg test, -- but it turns out the 25-foot time off because of its variability may not be ideal to include. And so many people are moving towards using EDSS and the 9-hole peg test, which is a measure of manual dexterity.
And then in the clinic, similar to clinical trials, this is a problem as well because there are patients that we see, we know they're progressing, but the EDSS every year is completely stable and so we often rely on what the patient tells us in the clinic to understand whether they're progressing or not.
So this is another huge reason it's been difficult to find better treatments for progression in MS. It's because the measurement tools that we have and that we rely on and that regulators actually force us to rely on and clinical trials are limited. So this study just really quickly illustrates the fact that the EDSS is inadequate. When this was a study done by Stephen Krieger and colleagues in New York, but they looked at people with MS who had EDSS scores of 0. So absolutely no objective evidence of disability.
There are 25-foot times walks were stable, but when they got these patients to do these high challenged tasks of balance and upper extremity function, they found that these patients clearly had deficit. So just an illustration of the fact that our EDSS is inadequate and that we clearly need better clinical tools, including possibly digital tools that include both passive and active monitoring that may be useful. And again, this is where it's very clear that in clinical trials and clinical practice, we need to move away from exclusive reliance on clinical tools and include better clinical tools, but also parent clinical tools.
Imaging measures that are relevant and blood biomarkers that are relevant. And this is where, in the future, I envision that we may, as long as we can convince regulators, be able to move towards composite multimodal endpoints that more accurately reflect the clinical endpoints that we care about. And this is an example of, let's say, a relapsing composite multimodal endpoint might look like a progressive multimodal endpoint might look like.
So I hope I've been able to just set the stage to illustrate to you how MS disease course descriptors are clearly outdated, and we need a better way to describe MS and not rely on these categorizations that we did in the past. -- the greatest unmet need in clinical practice truly are treatments that target progressive disease mechanisms. And it's complicated to figure this out because progressive disease biology is complicated, and it's very clear that we need better clinical endpoints, which will need to include composite mutimodal end points. Thank you very much for your attention.
Thank you very much. So I'll go on here, and I'm happy to present Vidofludimus calcium differentiated mode of action, by being the first direct non activator, which was ever tested in multiple sclerosis. Next slide, please.
So what is Nurr1? Nurr1 is a member of the NRA family of orphan nuclear receptor transcription factors, and it's expressed in microglia astrocytes and neurons. And they had regulated transcriptional programs which are involved in no neuronal maintenance and survival.
Well, therefore, -- it's no 1 can be associated with different neurological diseases. And by its expression in mid-brain dopaminergic neurons, cortical and subiculadglutamad Terje neurons, Nurr1 is associated with different neurological diseases beyond MS, such as Parkinson's disease, Alzheimer's disease, ALS, schizophrenia and other neurodevelopmental disorders. And this could allow a broader indication spectrum for the use of vidofludimus calcium in the future.
But today, we focus on multiple sclerosis. In studies of relapsing MS, it was shown that reduced Nurr1 expression is associated with higher relapses rate and higher EDSS scores and Nurr1 expression normalizes turn frequency coinciding with reduced MS disease activity. And there is a valuable research supporting the relevance of none in progressive MS.
The Panciera publication showed that in post-mountor cortex, HINO1 expression is associated with greater neuro preservation supported by higher neural density and lower lymphocytic infiltration what you see in the depicted picture here. And it showed us well that nuclear, Nurr1 expression in Layer 3 correlated with an older age at death, longer disease and longer time to wheelchair. Therefore, we think that a drug which affects the expression and activity of Nurr1 is a valuable option treatment option for progressive mass. And later on, in the CALLIPER session, we'll hear more about it.
Next slide, please. Yes. And here, we come to vidofludimus calcium, which provides a differentiated dual mechanism approach for the treatment of MS. So Vidofludimus is a direct 1 activator, which therefore may support neural resilience under inflammatory conditions and oxidated stress conditions.
Preclinical findings suggest that vidofludimus has both direct and indirect neuroprotective mechanism. In vitro, in cell culture assay, vidofludimus calcium promoted neural survival and reduced neurotoxic signaling of activated microglia industrial sites. And in vivo, even in an inflammatory EAE model, the vidofludimus calcium increased BDNF levels and expression of non-regulated target genes were consistently increased with Nurr1 pathway activation.
So in addition to the direct and potent activation of vidofludimus, which clearly differentiated from other medications used in MS vidofludimus calcium is a selective DHODH inhibitor and thereby, it contributes to anti-inflammatory effects, but by only targeting highly metabolically active TMB cells with no indication of broad immunosuppression, reducing EBV rate activation might be beneficial in addition.
So how is Nurr1 involved in Europrotection? As I said, no 1 is a nuclear receptor and a transcription factor, and therefore, it mediates its effect via gene regulation. This happens directly in neurons, but also indirectly via microglia and astrocytes. In neurons, which are depicted here on the left. And you see that neural survival and differentiation is addressed via upregulation of BDNF and GDNF, for example.
Whereas functionality of dopaminergic neurons by better neurotransmission is addressed via the upregulation of direct target genes like tyrosine hydroxylase and remer. In addition, the reduction of oxidative stress and improvement of cellular energy production is mediated by direct target genes like SOD1 and Cox 5B and further supports the neuronal resilience here.
Coming to the gliacells on the right-hand side, we see that activation of Nurr1 in microglial astrocytes reduces neurotoxic cytokines like IL-1 beta and TNF alpha as well as reactive oxygen species and nitric oxide. This prevents clear cell-driven neurotoxicity in the brain. The impact and relevance of reduction of microdel activation is broadly discussed and shown for BTK inhibitors, for example.
Here, we investigated in vitro the effect of vidofludimus calcium on cytokine production upon LPS induced activation of human microglia cells and demonstrated a significant reduction of those cytokines with already low doses of vidofludimus calcium. This shows that Vidofludimus is able to reduce microdel activation.
But what does it mean for Nurr1 survival, so therefore, we investigated Vidofludimo's impact on neuronal survival in the coculture of activated microglia and neural cells. And on the right in the graph, you see that Vidofludimus calcium was associated with increased neuronal viability in inflammatory co culture.
To demonstrate a direct neural protection by vidofludimus, which is independent of activated microglia cells. We used neurotoxic agents like TNF alpha cycle or what you see on the right-hand side, like 6-OHDA to trigger apoptosis in these neuronal cells. And in these test systems, Vidofludimus was able to significantly improve the neuronal survival.
To further demonstrate the relevance of Nurr1 here for vidofludimus calcium mediating neural survival, Nurr1 was knocked down. And this abolished the neuronal survival benefit of vidofludimus leading to the conclusion that vidofludimus requires Nurr1 for its direct neuroprotective effect.
To further strengthen the neuro protective properties of Vidofludimus and the new 1 relevance, we investigated the impact of teriflunomide, which is a DHODH inhibitor approved in RMS and we use the same in vitro test systems. And here, you clearly can see that compared to vidofludimus on the left-hand side, teriflunomide, on the right-hand side did not significantly improve survival of neuronal cells. And this is most likely explained by teriflunomide lacking binding towards Nurr1 protein, which was tested in 2 different biophysical methods, namely ITC and DSF and again, here, you see vidofludimus clearly demonstrated binding towards Nurr1 protein, whereas Kerplonomite did not.
So based on the preclinical data presented here, on activation and DHODH inhibition might offer a perfect treatment option for the whole spectrum of a mass Together, they may reduce inflammation, limit harmful microdel activity in the brain and directly help neurons to survive.
Thank you. With this, I would like to hand over again to Devon.
Thank you very much, Hella. So I'm back again. And this time, since we've already set the stage and heard a lot about the neuroprotective effects of Vidofludimus. I will just continue on with the discussion about considering patient populations within clinical trials and how we might use both imaging and fluid biomarkers and and a progressive MS clinical trials and in practice because clearly, the reliance on some of these clinical endpoints is problematic.
So in the last number of decades, I think it's very clear in the MS field in part because of the successes of treatment again that -- and in part because of rapidly changing diagnostic criteria that allow us to diagnose really with the first clinical presentation, but even now in some situations, even before the first typical clinical presentation, the face of MS that we are seeing now, and specifically that we're recruiting in clinical trials is very different what we were doing decades ago.
And so when you actually look at the annualized relapse rate that's been observed in clinical trials and specifically in placebo arms over the years, clinical trials that were done back in the early '90s up to the -- almost the millennium. -- reported annualized relapse rates, which, as you know, is the primary end point in relapsing MS clinical trials between 0.5 and 0.87. But when you look at annualized relapse rates that have been reported in more contemporary clinical trials within the last 6 years, as you can see, the ARR has dramatically decreased and sometimes is reported at 0.01 to 0.15.
So it's really clear that this primary endpoint that we use and entirely rely on in Phase III clinical trials of relapsing MS, has decreased dramatically over time because of all of the reasons that we talked about. And there really has been a nearly 80% to 90% reduction on this measure that we're reliant on it's very clear, again, in the modern era of MS and specifically MS clinical trials, prior clinical endpoints may no longer be sufficient to use because of the changing pace of MS.
And then as we discussed in the prior presentation, it's also very clear based on contemporary MS clinical trials that progression is not something that only happens at the end stages of disease or in progressive subtypes of MS, but again, happens across the entire disease spectrum, even in very early relapsing MS.
And so based on this, really, the face of MS is changing based on what we simply observe from clinical trials so that these clinical endpoints that we still rely on for Phase III trials are really not the same and are not as sensitive. We recognize that disability is happening even in early relapsing MS. We recognize that relapsing disease activity based on MRI findings is happening even in progressive MS.
And so this raises this really important question given all of this and that everything that we thought is shifting, how do we build these facts into upcoming MS clinical trials, so that we may still adequately test drugs that we think have very unique mechanisms of action and can address some of these unmet needs that we still clearly have in clinical practice. So where should we go with clinical trials?
So first of all, given all that we discussed, that MS is a disease spectrum relapsing and progressive disease biologies happen across the entire disease spectrum. We see this clinical endpoints that we used are likely no longer adequate. The question that comes up is -- when we're thinking about MS clinical trials, do we really need to restrict for specific MS subtypes in clinical trials, given that we know that both disease biologies happen.
And so in a way, with this knowledge, we should be thinking about clinical trial inclusion criteria and criteria should reflect the underlying disease biology that you think a drug target rather than relying on these outdated clinical phenotypes. So this is something that, as a field we most definitely need to think about because if we want to test drugs that we know have a very clear mechanism that addresses some aspect of MS disease biology, then we should think about inclusion criteria that go beyond the simple clinical designation and include people that have that biology of interest.
In addition, again, based on the mechanism of the drug, we need to thoughtfully come up with inclusion/exclusion criteria. Because we need to target appropriate populations for specific drugs. So if you know that a drug targets a specific aspect of MS pathophysiology. Net, for instance, that might neuroprotect or a certain aspect of chronic inflammation, then you want to target an appropriate population for a specific drug that you know is enriched in the type of pathophysiology that you think the drug can target so that you can detect a meaningful effect on that mechanism of disease biology that you want.
And so essentially, this means that when we're thinking about inclusion and exclusion criteria rather than relying simply on these clinical phenotypes, we need to think about what is the drug that you have, what is the mechanism that you're targeting? And what population can we recruit that has enough of that mechanism that we think this drug benefits, so that we can meaningfully show an effect if it's there.
And so again, this leads us to the conclusion that with clinical trials, reliance on these clinical endpoints may be outdated and it's very clear that we need more sensitive ways to detect whether a drug has an effect on the disease biology of interest, and we need clinical or endpoints that are a composite of clinical and other endpoints that reflect what we're trying to measure.
And so very clearly, we need more sensitive measures, which likely will include inevitably clinical measures, but also paraclinical measures, enhanced clinical measures and these biomarkers, so imaging and blood biomarkers that reflect the outcomes that are of interest to us.
In addition, this concept of enrichment is really important. So it's not just the end points that we need to figure out how to do better. But again, at the very beginning of the trial, when we're thinking about inclusion criteria, we need to include a trial population that we think has a lot of the disease mechanisms that a certain drug is likely to benefit.
And so we actually already do this in MS clinical trials for relapsing disease, where with most relapsing MS clinical trials will recruit people who have had frequent relapses in the years prior to enrollment or have MRI evidence of relapsing disease activity, which is either gadolinium-enhancing lesions or T2 lesions.
And the question comes up, now that we clearly understand that the unmet treatment need in MS are definitive treatments that target mechanisms underlying progressive disease biology -- how are we going to enrich for people who have an abundance of progressive disease biology and the mechanisms that you want to target with specific drugs.
And this is where some imaging biomarkers may have an important role. In the MS field, there's been a lot of interest in imaging paramagnetic rim lesions or PRLs or pearls. And this is simply an imaging measure that we think reflects chronic active lesions, which we know are one important, but not the only component of progressive disease biology.
So many studies have been done. We know PRLs are linked to having greater disability. But what is really interesting is that -- when you look at recent post-hoc analyses from some of the BTKI clinical trials, it turns out having a PRL at baseline greatly increases your risk of developing disability over a trial period of 2 to 3 years.
So as you can see from this diagram here and just focus on the gray bars, when somebody had 0 PRLs, the risk of disability progression in the HERCULES trial was 21%. But when an individual had 4 or more PRLs, the risk of disability progression prospectively over the clinical trial period was nearly twofold.
So this is a way that potentially in clinical trials moving forward, we can kind of address that issue of enrichment for progressive disease biology because it maximizes our chances of seeing if a drug has an effect on the biology that we are interested in targeting.
In addition, PRLs are potentially being looked at as measures of treatment response and very recently in the Pentucket and Penhance clinical trials this BTK inhibitor showed a reduction in the percentage of patients who had an increased PRL count at the end of the study. So it seems like that there is potential for enrichment with this imaging biomarker as well as potentially as a biomarker of treatment response.
In addition, an alternate way that we image chronic active fusions other than PRL is something called slowly expanding lesions, which is a technique when you have few MRIs in the same person over time, you can see if a lesion slowly expand. And there seems to be quite a bit of potential for use of this measure as a measure of treatment response in progressive MS trials.
From the CALLIPER study, people treated with Vidofludimus showed a reduction in the number of new cells at the end of the study in comparison to those who are treated with placebo, -- and again, in the fenebrutinib Phase III clinical trial, cell count and cell volume were reduced in people who are treated with fenebrutinib in comparison to the active comparators.
So both of these imaging measures, there are different methods to detect the same thing, which are chronic active lesions a major driver of progressive disease biology seem to have potential as an enrichment biomarker as well as a biomarker that reflects treatment response.
In addition, blood biomarkers. I don't want to go into too much detail about this, but things like NFL and GFAP, it seems when you use them smartly, may be able to reflect not just relapsing disease biology, but also progressive disease biology, particularly when you think about timing as well as combinations.
So again, we land on this slide that you've already seen, where ultimately in clinical trials, it's clear that we need to move away from exclusive clinical endpoints to more composite multimodal end points.
So I'm just going to end by saying, clearly, the base of MS has changed previous clinical endpoints that we relied on need to be revisited. And so when designing future clinical trials, we need to think about inclusion criteria and endpoints, thank you very much.
Thank you, Jiwon. Thank you so much for diving into progressive MS clinical trials, patient populations and to different biomarkers and endpoints. We really appreciate your insights.
I would like to bridge to our next speaker, Maria Pia Sormani, who will continue diving into these details and more look at clinical and disability end points. Maria Pia Sormani, full Professor of Biostatistics at the University of GenoaItaly is an internationally recognized biostatistician with over 25 years of impactful contributions to MS Her work has fundamentally shaped clinical trial design, surrogate endpoint validation and data-driven decision-making NMS worldwide.
Her contributions bridge methodological innovation and clinical applicability with direct impact on patient care and regulatory strategies.
Maria Pia, over to you.
Thank you, Jessica. Thank you very much for this kind introduction. And in these 10 minutes, I'll try to show you some issues we have with clinical trial design and endpoints for progressive MS. So Jiwon clearly explained, we are going through a new vision of MS. We are passing from rigid clinical labels to a biological view of MS as a unique disease with shared biological mechanism. However, even if our vision is changing, our approaches are still breached. And -- this is the classical standard development of a drug in MS.
We have a Phase II based on MRI lesions, a Phase III based on relapses usually in the relapsing forms of the disease and then separate fast trial to address some effect of the drug on visibility. This scheme has worked for many years because we were testing drugs with very similar mechanism of action, mainly anti-inflammatory drug with a strong effect on acute inflammation.
But of course, we are having this approach is less effective if we want to test the effect of the drug on the progressive biology. So here, we have the endpoint challenge in -- for progressive MS trials. First of all, we have a few biomarkers. And the biomarkers we are using has a lot of limitation. So for designing a Phase II in progressive MS is always an issue. The classical, the standard biomarker we have used so far for Phase II studies in progressive MS is brain atrophy, but brain atrophy is a very specific market is the volume of the brain.
So it's not linked to any specific mechanism. And recently, it gave inconsistent findings. We had some positive press on visibility and negative on an atrophy or passives. Jiwon alluded to the MRI markers of chronic inflammation like paramagnetic rim lesions and slowly evolving leisures, I mean, their biology is clear.
We are pretty sure that they are markers of chronic inflammation, but they are still under investigation as endpoint for clinical trials. We still don't have a clear quantification of these biomarkers to be used as endpoint in clinical trials. Well, Jiwon also alluded to the limitation of clinical endpoints. The EDSS has limited sensitivity to change is heavily weighted towards ambulation, and it does not cover the full spectrum visibility.
For this reason, now in progressive trials with those relapse in meeting trials, we use composite endpoints, integrating EDSS with other functional end point. But this causes some issues with regulatory acceptance and sometimes also in the interpretation. And -- why -- I mean, we need different endpoints. This is just an example about what happened to confirm disability progression. That is the standard disability endpoint since the first clinical trials in MS the event rates declined over time exactly as the relapse rate has declined a lot over time.
The same happened for disability progression events also because we are now forced to use Aticompartor. So while in the early 2000, the rate of event for confirmed disability progression was around 25%, now has dropped incredibly. And in recent trials, it is below 10%. So I mean it's quite impossible to demonstrate the superiority of the drug for such low rate of events.
I'm talking here of relapsing MS. So in progressive MS, the rate of events is a bit higher, but anyway, it declined over time also for progressive members. So composite endpoint, the composite confirmed disability progression is a standard composite that is also accepted by regulators and is made up of 3 different components. So patient is defined as progressed if we progress on EDSS or minor back test addressing uplink function or time 25-foot work addressing working ability.
So of course, a combination of endpoints in the nonstation increased the number of events. It is sufficient to be progressing 1 of the 3 components to be defined as progressed. However, more events does not automatically translate in higher sensitivity to detect treatment effect. Here, we have a list of trials the red tiers are those where the confirmed disability progression based on EDSS alone was more sensitive and the blue are those where the composite was more sensitive.
You can note that even if the higher number of events gives narrower confidence limits Sometimes, the visibility based on EDSS alone has lower as a ratio. So you must find the balance of a higher number of events and more specific outcomes because if you add noise, you can't have a treatment acting on noise, if the noise always dilutes the treatment effect.
So this is why our -- I mean, group of statistician is trying to propose new methods for combining end points in composite endpoints. Here, I'm showing you an example coming from oncology, the approach based on the net benefit. The net benefit approach instead of taking the average effect the average number of events in both groups and taking the ratio compare each treated patients with each controlled patients.
So you will have a lot of comparison. And for each comparison, you evaluate who is the winner. If the -- I mean the treated patient is better than the controlled patient, you will have a win. If the control is better, you will have a loss. Otherwise, the 2 patients has the same outcome, you will have a tie.
So the next benefit is the excess of wins over losses or on a relative scale, you will have the win ratio that is the ratio between the wins and the losses. In this way, it is possible to combine in a unique way, a combination of endpoints. So you must create a hierarchy based on the most important outcome followed by all the others, and you evaluate each pair based on the most important outcomes.
If you have a win or a loss, you stop, but if you have a tie you go for the second outcome. So here is a random list. We put this ability as the first bring volume process. Second relates as a third and so on, you can include also patient-reported outcomes and other outcomes in the list. And you can create a very long list in order to eliminate the ties and keep into a single measure the effect on different endpoints.
So the interpretation, if you have a net benefit of 15%, this means that over 100 patients, you have 15% more wins than losses or on a relative scale, a win ratio of 1.5 means 1.5x as many wins as losses. This approach, interestingly, can be also applied to EDSS improvement and worsening. Please note that EDSS improvement is a relevant endpoint, especially for drugs showing neuroprotective effect because these kind of drugs can cause an improvement in the clinical disability.
So it is important to take also into consideration the possibility of the fact is an improvement. However, regulators, I mean, they don't trust improvement if they don't have an effect on worsening first. So with this net benefit approach, we can combine in a single measure improvement and worsening. You compare 2 patients, for example, on improvement first and that is you don't have a win or a loss of improvement, you can compare them on worse. And here, it's an example on CALLIPER.
CALLIPER was the Phase II clinical trials in progress internet evaluating Vidofludimus calcium versus placebo, 200 patients per arm, approximately. So a very low number for having the power to see an effect on visibility. The study was negative on the primary outcome that was brain volume, but there was some signal on the 24-week composite visibility progression.
Interestingly, the drug was -- had also a very strong effect on improvement. So the possibility to improve -- the risk of improvement was doubled in patients treated with Vidofludimus calcium versus placebo. With a win ratio approach, and so combining all the wins of all the losses comparing each patient to each other in both arms. And comparing if the patients improved, more stable or worse, the win ratio was 1.55 and the p-value was significant.
So this approach includes improvement and worsening. So it can be accepted by regulators. And in a single measure, bring all the information we need about the effect of the treatment. So this is interpretability of this measure, but I already talked about that.
So a conclusion. Jiwon clearly stated that new outcomes must be explored for progressive MS. So this is something that we continue to talk about, but we are still very locked in the standard approach. So we are -- the primary outcome of our clinical trial is still comfortability progression.
New methods, new standard methods can be evaluated for Compass endpoint. This is for free because, I mean, it's not it does not imply collecting new kind of endpoint, but just the way for optimizing what we have collected. The net benefit and the ratio can summarize multiple outcomes according to a prespecified clinical hierarchy.
This is their use also incorporating patient-reported outcomes. The EDSS outcomes, so worsening an improvement must be evaluated especially for drugs that are expected to have a neuroprotective effect. And also patient priorities can inform the hierarchy. So the hierarchy can be different according to different patients perspective, so creating a very patient-oriented treatment effect measure.
And that's all on my side.
Great. Thank you so much, Maria, and thank you, Jiwon. So I'm going to start next but I'm not going to have a lot to add to sort of those great presentations from Jiwon and Maria Pia and of course, Hell's introduction. As we go into where we're headed, with our progressive MS program.
Next slide, please. So I think understanding, we don't have to go much into the unmet need. It's been well established now. I think in this conversation by others, meant need here. And this title of potential to change treatment paradigm. I don't say that lightly. I think that it's unusual to be in a situation where you have a compound with a potential mechanism that targets what we believe is the underlying process.
I want part of the underlying progressive process and multiple sclerosis throughout all stages of disease. And then at a time when progression is becoming an increasingly realized is such a core element from disease onset that there is that potential to introduce a new approach with novel drug trial design and lead to an understanding and hopefully benefit to people with the disease, again, targeting that core underlying concept.
Next slide. And that's sort of what's shown here and already has been described. We are -- it is increasingly clear that this is -- the progression in MS is a continuum of a common underlying process from the earliest stages I think this just summarizes some of what's already -- was already highlighted by Jiwon in her presentation. But where we are now with the environment and our understanding of the disease is really a perfect time to take into a progressive study, a compound with a potential unique mechanism as well as pulling in some of these learnings to help evaluate a potential benefit.
Next slide. And this is the study design of caliper now. So the Phase II study, Maria mentioned the study. This is some of the inclusion criteria on the left. The study design on the right. I think the -- a couple of things just to point out. First of all, it's a large study. This is a very large Phase II study, 467 patients, most of whom are still in the open-label extension study with a follow-up of of nearly 6 years or so in many of these patients.
The other unique aspect, it was a pooled progressive population. And this is sort of what's the biology and our understanding of the disease is telling us that these people if you're going to treat the underlying progressive portion of the disease, whether they're relapsing onset or progressive onset, you should be able to study these populations together, and that's what was done here and you can see the distribution.
And on the next slide, you can also see a little bit more of the demographics. This is a very typical progressive population. Slightly older than in the relapsing study with a higher EDSS score of 5.5 median. No relapses in 2 years prior to coming into the study. Nonetheless, some inflammation detected at baseline 16.3% on got a lesion at baseline. So mostly nonactive patients and a very long duration of disease and about -- again, about about nearly 60% of your nonactive secondary progressive.
Next slide. So as already pointed out, they missed the primary endpoint of brain percent change in brain volume. Now I think in retrospect, as Maria Pia highlighted, it's the limitations of this outcome measure, I think, are manifest here. I mean you have now looking back with what we know, we know that this endpoint does not necessarily reflect clinical progression and there are -- so there are studies that demonstrate clinical progression negative on this endpoint and positive in this endpoint and no effect on clinical progression.
So in retrospect, we know now that this is not a great endpoint for a progressive study. But this study given its size and the endpoints that were captured teaches us an enormous amount about vidofludimus, about the disease and makes us feel really comfortable and excited about proceeding into a follow-on study in progressive MS.
A couple of the interesting observations also is we had a nice effect on regional atrophy. Regional atrophy tends to be a little bit better. at reflecting being reflective of changes in progression and particularly thalamic changes, as you've shown. These are nonsignificant but nonetheless, some meaningful differences.
Next slide. Now the most interesting part of the results, I would say, are related to these clinical outcomes. Now we missed the primary endpoint. So these things -- we can't say these are statistically significant changes. I mean, in any sort of hierarchy -- but there's some very interesting trends. So first of all, left-hand side, 24-week confirmed disability worsening, right-hand side, 24-week confirmed disability improvement where worsening is an increase in ESS that sustained and improvement is a decrease in the EDSS that is sustained each for 24 weeks.
What you're seeing on the left is that across these subgroups of nonactive secondary progressive and primary progressive, you're seeing a really interesting and pretty consistent change that favors you to Vidofludimus calcium. Even more interesting, on the right-hand side, looking at improvement when one looks at the overall patient population and the effect of Vidofludimus on confirmed disability improvement, the trial achieved nominal statistical significance. So there was a significant nominally significant p-value 0.034 parent effect on the overall improvement of the pooled population and very, very consistent changes in that direction through the subgroup. So very encouraging results that made us excited about continuing to explore these effects.
Next slide. This is another result that was encouraging regarding the potential effect on disability. This is the change in volume of new enlarging T2 lesions. Significant nominally significant effect over time. But as you can see, increased as you see the accumulation of lesion volume in the placebo group, a reduction volume in the active group.
Next slide. Jiwon already pointed out the effect on cells. Again, a very encouraging result considering it's predictability for chronic inflammation.
Next slide. And then we went into the now. We just looked into the extension study, looking at whether these effects were maintained, and this was just presented at the MS Toronto meeting. And you can see pretty clearly that the disability slowing of worsening and disability improvement effects were maintained -- through the recent cutoff of the open-label extension study with the apparent effect increasing. So all of these signs made us feel comfortable about proceeding into a confirmatory Phase III study.
Next, and even more interesting and exciting was deploying the net clinical benefit as Maria Pia already pointed out to the CALLIPER study, where the win ratio 1.5x more likely to have a win, namely disability disability outcome on the Vidofludimus calcium versus placebo. This -- if this had been the endpoint of the study, we'd be having a very different conversation now. So now it's the time very excited to be able to repeat this, confirm this in a larger pooled population. Next slide. And you cannot have a discussion of clinical study of this size certainly without discussing safety. The safety profile remains favorable, 1 of our strongest assets as we head into a drug that has the potential to have these meaningful types of benefit with a favorable profile.
Next slide. And this is another factor that makes us pleased with the overall profile and the retention, the conversion to the phase from the main treatment period or the double mind period into the open-label extension period and how much -- how many patients transitioned and remain in that study. And all of this just as I didn't point out earlier, all of this is with the 45-milligram dose flu which will be the dose that we're taking into the next Phase III study. So let me tell you about that study. So the name of the study is PROTECT MS. That's as -- the name is listed here.
Next slide. Inclusion criteria, the PROTECT MS study population is similar to what we recruited, who we recruited for CALLIPER. We're trying to match the patient population to the greatest distant possible. You can see washout period there will be required for people coming off an anti-CD20, but there will be other washouts as relevant. We're trying to get the whole spectrum of progressive MS patients. We don't have any exclusion criteria for drug-drug interactions, other things of that nature and anticoagulant as an example, as we head into this initiation, which is currently underway.
Next. This is the study design. The objective is to determine whether Vidofludimus impacts disability progression and progressive people with progressive MS, targeting about 1,400 patients Vidofludimus versus placebo. It is a variable end study. So we're going to be stratifying by the subtype of progressive MS as well as EDSS score, following them over time. It's a variable ending, meaning it will be a required number of events before we -- that allows us to monitor these slow event rates that are now, as described, occurring more and more often, but also we're including inverter analyses to assess the futility along the way, to adapt the sample size as necessary and potentially enable stopping sometime over the course of the study due to a meaningful effect on efficacy.
So next slide, end points. Primary endpoint is time to 24-week confirmed disability worsening or 9-hole peg test, so we're going in the direction of the composite. But equally as important, some of our secondary endpoints around confirmed disability improvement, net clinical benefit, as currently described is our really featured high in the hierarchy and as well as these key imaging outcome measures that we believe will help us to best understand the biology of the disease and our impact on the biology of the disease as well as our impact on people with the disease through a variety of PROs.
They're going to tell us how does this profile benefit these people who really, as of now, have no effective treatment. And of course, standard safety assessments would be performed throughout the study.
Next slide. So just in summary, we believe there's treatment paradigm changing potential, both in how we both in the mechanism of the drug as well as how we expect to evaluate this drug. We have really interesting strong imaging and exploratory disability signals that we've seen in this large Phase II study, CALLIPER, favorable profile at the 45-milligram dose. And the some of the observations and the nonactive patients make us really optimistic about the NIR mechanism, and we are as I've mentioned, we're initiating studies currently, and we anticipate the first patient to be enrolled in the first half of 2027.
So with that, I'm going to turn it over to Jason.
Thank you, Mike. We expect much of today's presentation discussing the underlying biology progressive MS, the clinical challenges facing patients, the clinical development challenges facing drug developers and the potential of Vidofludimus calcium.
I'd like to shift gears now and spend the next few minutes to discuss what this means from a commercial perspective and why we believe Progressive MS represents such a significant opportunity for both Immunic and Vidofludimus calcium.
Next slide, please. Despite the tremendous progress that's been made in treating relapsing MS over the past 3 decades, Progressive MS remains one of the biggest challenges in neurology. Approximately 25% of diagnosed MS patients have progressive disease. These patients face increasing disability, declining independence and significant burdens on families and caregivers.
Treatment options remain limited. And even where therapies are available, their benefits can be modest, particularly for patients without active inflammatory disease. What makes this opportunity especially compelling is the convergence of several factors: Significant unmet medical need, clear physician demand, an evolving competitive landscape and a large addressable market.
Importantly, we believe this is a real opportunity for a differentiated therapy like fetoflemius calcium to address both nonactive secondary progressive MS and primary progressive MS while potentially offering a favorable long-term safety and tolerability profile. Next slide, please. The burden of Progressive MS extends well beyond the clinical manifestations of the disease as disability accumulates health care costs increase substantially.
On the left, you can see data showing that annual health care costs for patients with nonrelapsing SPMS are approximately 2.4x higher than for match individuals without MS. For PPMS, the difference is even more striking with costs approximately 4.5x higher over a 2-year period. And these figures don't fully capture the broader economic burden, including loss productivity, early retirement, home modifications and informal caregiving.
The important takeaway is that disability progression is extraordinarily costly, not only for patients and their families, but for health care systems. And therefore, a therapy that meaningfully slows disability progression to therefore deliver substantial value to patients, their families and caregivers and the broader health care ecosystem.
Next slide, please. As we heard from Dr. Oh during her presentation today and further highlighted in the slide, the need for additional therapeutic options in progressive MS is clearly recognized by the physicians who treat these patients. This slide summarizes market research conducted with both generrologists and no specialists, showing that new treatments targeting PIRA or progression independent of relapse activity as well as new therapies for primary progressive MS and non-active SPMS ranked among their highest priorities. It's also important to note that while neurologists are eager for new therapies that can meaningfully address disability progression. They also emphasize the importance of safety, tolerability and convenience, particularly in this older, more vulnerable and often difficult to treat patient population.
From a commercial standpoint, these findings demonstrate not only strong physician demand for new treatments, but also the importance of developing therapies with a differentiated overall profile, reinforcing what we believe is a compelling opportunity for Vidofludimus calcium.
Next slide, please. When we look at current treatment patterns in progressive MS, the dominance of anti-CD20 therapies in the U.S. market is understandable. -- particularly given that Ocrevus remains the only FDA-approved disease-modifying therapy specifically indicated for primary progressive MS. As you can see, based on physician reported data, anti-CD20 therapies account for approximately 80% of disease-modifying therapy treated patients in PPMS and about 55% of treated patients in non-relapsing secondary progressive MS.
These therapies, specifically anti-CD20 have fundamentally changed the MS treatment landscape, mainly through their ability to effectively suppress inflammatory disease activity. However, while controlling inflammation is critically important in relapsing disease, it does not necessarily address all of the underlying biological processes driving disability accumulation in progressive MS. And that helps explain what we're seeing in the next slide.
Next slide, please Jessica. So while disease-modifying therapies, particularly the anti-CD20s, are widely used in progressive MS, many patients continue to experience disability accumulation. Although a significant portion of progressive MS patients are receiving treatment, physicians report that only 37% of patients on a disease-modifying therapy are responding well.
The remaining patients are either experiencing suboptimal responses, have tried or failed treatment or have never received a disease-modifying therapy. So the issue isn't simply whether patients are receiving treatment. It's whether those treatments are adequately addressing the underlying disease process responsible for disability progression.
And to better understand why this remains such a challenge, it's important to look at how disability actually accumulates in progressive MS.
Next slide, Jessica. As we've discussed throughout today's presentation, much of the disability accumulation progressive MS occurs independent of relapses or PIRA. It's in an important paper push by Fred level at all in 2022, the investigators found that approximately 80% of confirmed disability worsening events in both secondary progressive MS and primary progressive MS were attributed to sustained PIRA -- in other words, the vast majority of disability worsening these populations incurred independent of inflammatory activity.
And because the current therapies are highly effective at controlling acute inflammation disease, they may not adequately address the chronic inflammatory or compartmentalized inflammation within the central nervous system that contribute to PIRA. And this is precisely where we believe the Vidofludimus calcium could offer a differentiated approach.
Next slide, Jessica. What we believe truly differentiates Vidofludimus calcium is its ability to directly activate Nurr1 a mechanism associated with neuroprotection and neuronal survival. As Hella discussed earlier, Nurr1 plays an important role in maintaining neuronal health and protecting neurons from an inflammatory and oxidative stress. And that is particularly relevant in progressive MS, where neurodegeneration is a major contributor to disability accumulation and remains inadequately addressed by currently available therapies.
But beyond its mechanism of action, we believe the overall product profile could be particularly compelling in progressive MS, especially given the importance of long-term safety, tolerability and convenience in this older and again, more vulnerable patient population. Based on the clinical experience generated to date, Vidofludimus has demonstrated not only encouraged efficacy in progressive MS patients, as Mike just highlighted, but a safety and tolerability profile that could be highly differentiated.
So for a successful and demonstrating a clinically meaningful benefit on disability progression in the Phase III study, we believe Vidofludimus calcium could offer physicians something particularly compelling in oral therapy with a differentiated potentially neuroprotective mechanism and a profile well suited to the long-term management of Progressive MS.
Next slide, please. Of course, we're not alone in recognizing the significant opportunity in progressive MS. The development landscape is becoming increasingly active with several late-stage programs pursuing new therapeutic approaches. As you can see in this slide, BTK inhibitors represent a significant portion of the emerging pipeline alongside Sanofi's program targeting CD40 ligand. What we believe truly differentiate Vidofludimus calcium from these other programs is its potential for direct neuroprotective activity through Nurr1 activation, a mechanism, again, that can be particularly relevant at addressing PIRA.
Importantly, unlike most of the programs shown here, we're also pursuing a development program that will collectively go after both primary progressive MS and non-active SPMS. The 2 MS populations with a particularly substantial unmet medical need.
Next slide please. When we look more closely at the near-term competitive landscape, it's clear that significant opportunities remain for therapies that can meaningfully address disability progression while offering a favorable benefit risk profile. I think starting with OCREVUS, the only FDA-approved disease-modifying therapy for PPMS, it's establishes tell as an important treatment option, but its efficacy has been relatively modest, particularly in older patients with less inflammatory disease activity. And long-term B-cell depletion raises important considerations around infection risk and declining IgG levels, especially again in an older, more vulnerable patient population.
Turning to fenebrutinib, a BTK inhibitor currently under regulatory review by Roche. This drug demonstrated noninferiority to OCREVUS in a Phase III study in MS However, its development program has raised safety considerations, including liver enzyme elevations and a numerical imbalance in depth.
And finally, tolebrutinib, another BTK inhibitor developed by Sanofi demonstrated a benefit on disability progression in nonrelapsing SPMS, However, Serious safety considerations specific to liver and regulatory challenges have complicated its path to market. The FDA issued a complete response letter late last year, and its European approval is restricted to adults with nonrelapsing SPMS who have not experienced a relapse in the preceding 2 years.
Now I want to be clear, OCREVUS will undoubtedly continue to play an important role in progressive MS and BTK inhibitors, if approved, could provide physicians with a much-needed additional mechanism of action. But the introduction of a new treatment options doesn't eliminate the need for continued innovation, again, particularly in a disease where disability progression and safety remain such a significant challenge. And this is where we believe Betaines calcium can win.
Next slide, please. So let's translate into the size of the commercial opportunity. This is a large and white space market today. We estimate there are approximately 175,000 diagnosed patients with secondary progressive MS and PPMS in the United States of whom approximately 115,000 are currently receiving disease-modifying therapies, including many who are currently being treated off label. Based on our current net pricing assumptions, that represents an estimated annual commercial opportunity of up to $13 billion in the United States.
In Europe and the U.K., we estimate another 165,000 diagnosed patients with approximately 60,000 currently receiving therapy. This translates into an additional estimated annual opportunity of up to USD 5 billion. So taken together, we're looking at an enormous market opportunity of up to $18 billion annually across these major markets.
And importantly, we believe this market has potential to expand further as new therapies become available, diagnosis improves and more patients received treatment.
Next slide, please Jessica. But there's another dimension to the commercial opportunity that I think is particularly exciting. Today, most disease-modifying therapies for MS are approved for specific patient populations, whether it's relapsing forms of MS or PPMS, et cetera. And as you've heard throughout today's presentation, our development strategy is designed to go beyond these traditional boundaries.
With our ongoing insure Phase III trials in relapsing MS and our planned Phase III PROTECT MS program in progressive disease, we're pursuing the potential to treat patients across the full spectrum of the disease. If successful, Vidofludimus calcium could potentially become the only disease-modifying therapy with indications spanning across all of the MS subtypes shown here.
And we believe this could represent a particularly compelling commercial proposition. Not only could it provide physicians with a differentiated treatment option across the multiple stages of MS, but it could also strengthen the familiarity and confidence in beautiful and is calcium, potentially supporting its use throughout the course of the patient's disease.
Next slide. And I'll close it to what I think this could mean for Vidofludimus long-term commercial potential. We believe that Vidofludimus calcium in the near term. has the potential to become a blockbuster product in relapsing MS alone. And we're now just a few weeks away from the Phase III ENSURE readout.
But what makes the progressive opportunity particularly exciting is the potential to build significantly upon that foundation. Given the substantial unmet medical need, the large addressable patient population and the limited treatment options available today, we believe success in progressive MS could add multiple billions of dollars in incremental peak annual sales.
And importantly, the opportunity could extend well beyond those incremental revenues. If uniforms calcium demonstrates a meaningful benefit on disability progression, we believe it could create a powerful halo effect in relapsing further strengthening physician confidence supporting earlier use and potentially expanding its commercial opportunity across the broader MS market.
Taken together, we believe success in both relapsing and progressive MS could position deafness calcium as 1 of, if not the most important therapies in the treatment of multiple sclerosis. And ultimately, that's our ambition. -- not simply to bring another MS therapy to market, but to build a differentiated multibillion-dollar MS franchise with the potential to address patients across the full spectrum of the disease.
And with that, I'll turn it back to Erik.
Thank you so much, Jason. Thank you to all of our speakers. I'll be very quick because I want to get us over to Q&A. Just one slide for me. Just the last sort of value creation road map for the company as I started with, we have the ENSURE 1 and ENSURE Phase III studies in relapsing MS reading out in December, targeting an NDA submission next year commercialization in 2028. And that sets the frame, the foundation and the baseline for the company.
And in the midst of that, we are actively initiating the PROTECT Phase III study in progressive MS that Mike outlined just a few moments ago, expecting the first patient to be enrolled in that study in the first half of next year. And then we pending the success of that study, of course, we have the opportunity to expand and address into the progressive MS market. And as Jason just articulated beautifully, our vision here is really that vidofludimus calcium has the potential to affect people living with MS regardless of where they fall on the spectrum, really being the first modern development program in MS that acknowledges these trends that Gian articulated that MS is a spectrum disease, and we believe Vidofludimus calcium based on its underlying mechanisms has the potential to address all people living with MS.
And what you've heard about here today is our commitment to that vision and our plan to achieve it. So with that, I'm going to ask Jessica to moderate a Q&A session here for us. So Jessica, floor is yours.
Yes. Thank you, Erik, I actually see a lot of race hands here. So I'm happy to start the Q&A session. Given we are almost up on time, I would suggest we prioritize question for our 2 experts first, to be mindful of their schedules. Jiwon Maria Piaeer, if you need to drop at the hour, feel free to do so. Our management team will be happy to stay a few minutes longer and take additional questions. So let's jump into it. The first one I see here is Matthew [indiscernible] over at Stifel.
2. Question Answer
Can you hear me okay?
Yes.
This is Matthew on for Paul. And this was a very helpful event. So maybe a question for Dr. Jiwon your experience with MRI markers and research, maybe -- could you talk about like whole brain atrophy -- and were you surprised at all that there was no difference between drug and placebo in Phase II caliber? And then maybe a follow-up for management -- could you talk about the choice of confirmed disability worsening plus 9 hole peg test for the PROTECT MS study.
I think in Phase I, you had a hazard ratio of about 0.86 for the 3 components, including the time 25-foot walk test. -- how would that look like if you were to exclude that and just do the composite put the 2.
So maybe I can start with the brain atrophy question. So great. So the short answer is no. I'm not that surprised just because brain atrophy is an okay measure, but it's been problematic. And part of the reason is brain atrophy is not specific. It basically is shrinkage of the entire brain that's a delayed measure reflecting all of these different pathological processes that happen in a disease like MS. So -- there's a time lag issue.
There's a lack of specificity issue. And in many contemporary MS clinical trial, we've seen this discordance many times. And so say, in the Hercules tolebrutinib trial, there was a clear clinical effect. The brain atrophy effect was not seen -- similarly in Oratorialhand, -- this was the case as well. The clinical effect was not seen. The brain atrophy effect was nonsenand these are all Phase III clinical trials.
And then on the other hand, -- when you look at the MS STAT trial that in the Phase II trial showed a clear effect on brain atrophy, but the Phase III trial was a dismal failure. This kind of illustrates to us that in certain settings, brain atrophy is useful. But because of the limitations that I described earlier, it probably is not an excellent measure of progression in MS. So the short answer is no. It does not surprise me, and I don't think, especially given the trends that are seen with the clinical data, Overall, kind of clinical trends really trump all even -- especially when it comes to somewhat problematic MRI measures.
And why don't I jump in real quick on the endpoint. So -- we -- regarding the use of the 24-week CDW or Nope, I think, as you heard from ripe, this seems to add to the sensitivity. We've seen that -- the numbers you're -- Joe, if you were to just look at the 9 hope with the -- the numbers that we already showed you with EDSS alone, you get a bit more out of it than that, but it's around the same. It's around -- similar to what you're seeing in the just EDSS alone in this particular study, but we pick up a few extra events, which is, again, the purpose of going to a composite.
If I can add something. We recently published a study comparing across many clinical trials, the composite and with all the single components and not the possible combination. And the combination of EDSS with 90 tech test was the only combination adding something more more sensitive than EDSS alone in the progressive MS group. So this analysis underlies that -- I mean it's always a bet which component to combine. But -- in this case, the 90deg test and the EDSS in progressive MS seems to be the more evidence-based and more sensitive.
The next one I see here is Sam Slutsky over at LifeSci.
So I guess for the physicians, is both RMS and PMS, do you receive approval, how will this play in the first-line space? I know Dr. Joan previously indicated that we know progression starts early -- so would approval and both make doctors consider vidofludimus in the first line in younger patients? Just kind of curious on that play. And then -- just on enrollment in PMS separately.
Obviously, you touched on baselines or inclusion criteria, but obviously, prior studies have had certain biases on who they're enrolling between age or disease activity. Just kind of curious on how you think that could play on the control arm and just how you might stratify for that in your study?
So I can start. In terms of us should both endpoints be met in the Phase III clinical trials, in terms of first-line use, yes, it would be likely very commonly used first line for a few reasons. So first of all, we all use teriflunomide, which is a DHODH inhibitor somewhat commonly as a first-line agent and people with relapsing MS.
But as you saw from my slides, in people with relapsing MS, even at the beginning of disease, you often see evidence of PIRA and so this would be a very natural choice for people who have some relaxing activity, which technically with today's framework, we would still categorize as having relapsing MS because of -- if there is this effect in progression and especially neuroprotection, it would be a very attractive first-line agent because we know both disease biologies happen in most people at the very beginning of disease.
So it would make a lot of sense to try to address that from the beginning.
And I could answer about the patient populations. What we anticipate is very similar to what we saw in the CALLIPER study. We believe that progression is progression, and these patients are progressing, whether they've been phenotypically called primary progressive or phenotypically called secondary progressive, meaning progressive onset or relapsing onset.
So we would anticipate that our feasibility tells us that if we were to just recruit we would likely get a very similar scenario to what we've been -- what we saw in CALIPER. But actually, our -- I think, I would say that our ambitions is to and have more of the nonactive secondary progressive, quite frankly, because that truly is the need.
Next one in the queue here is Myles Minter over at William Blair.
Maybe the first for Dr. Oh and Dr. Sormani, -- the company is measuring net clinical benefit in the insure trials in RMS, and it's pretty high up in the stat hierarchy, you explained that end point really well today. If you did see benefit in an RMS population does that tell you anything about potential efficacy in a PMS population? That's the first one.
And then the second one, maybe for the company. What's the rationale for running one study with primary progressive and non-active secondary progressive dent placebo rather than running them separately and doing a trial against placebo instead of a non-inferiority study like we saw in Fentrepid.
Yes. Very good questions. Regarding the first question, I mean, the net benefit can be tested both in relapsing and progressive. It's a very crucial point is how to select the hierarchy of the endpoints because this can affect, of course, the measure, and it must be based on clinical reasoning.
Well, regarding the life running a single trial, I think that Mike alluded already to that, patients progressing are progressing. So taking all together, facilitate recruitment and also changes the focus of the aim of the clinical trials. The aim is to target progression. So if the drug is targeting progression, it must be useful in both subtypes.
The subtypes are somehow artificial. So I think it is a very modern approach to include both the phenotype population in the study. And I don't remember the third question. It was embedded...
It was just a question on why run and placebo-controlled study instead of a non...
Well, yes, that's -- that's a very good question. I would say that the placebo-controlled study is easier. So if it's possible to run such a study, it is much easier. A noninferiority study is a very challenging study -- and also, someone could argue that noninferiority to ocrelizumab is not satisfying anyway because we know that the effect of ocrelizumab in progressive MS is significant, but it's not so relevant. So I mean assessing on infertilizumab, I mean I think that new drugs are more ambitious. They want to really cause an improvement in progression delay in progression. So I think that the answer is because they are more easier and maybe interpretation is cleaner.
I think the second and third questions are related. There simply is not a standard of care to compare with or use as a control arm miles, there is nothing that is approved across the spectrum. And this is really truly where the puck is going, kind of mentality in terms of this trial, why would we include both because we fundamentally believe and the field is with us on this, Jiwon showed some of those papers at the top. The progression is progression.
And this sort of old world of sort of falsely stratifying across secondary or nonactive secondary and primary progressive is reflective of the view of MS 15 to 20 years ago. And as Maria Pia said, we do really truly want this to be the first modern MS pivotal trial. And we're aligning ourselves with the field. And we think in doing so, we're being true to the biology, the science and ultimately, the patient community and at the end of it, we end up with a data set that is extraordinarily unique in MS and broaden its potential applicability.
And just wanted to chime in from a clinician standpoint, we really don't think that there is any meaningful difference between SPMS and PPMS. So it makes sense in this modern clinical trial to group them together. And this trial is actually recruiting for nonactive PPMS and SPMS, which we really don't have any treatments for because most clinicians use ocrelizumab and siponimod for active SPMS and PPMS, so it makes sense to do a placebo-controlled trial because as Maria Pia said, it's the purest study design that allows you to look for a clear benefit, but also there is no standard of care right now for nonactive SPMS or PPMS.
Maybe a follow-up question here for -- probably for Mike on the split for SPMS and PPMS from Martin Fern and Wedbush for protective S, are we expecting a similar ratio of nonactive SPMS and PPMS patients as in caliber or will enrollment be weighted towards patients with PPMS.
I think as I've already said, I think we're going to -- we would anticipate something similar based on our fee early feasibility. But our -- since our goal is treating progression, we're going to get both.
The next one here is Matthew Caufield at H.C. Wainwright.
Excellent. Thank you to the team and Dr. and Sormani for the insights today. How much of the clinical influence observed and discussed from Caliber do you believe can be attributed to direct neuroprotection through NE-1 activation? -- rather than conventional anti-inflammatory effects. Thanks for any thoughts or specific points there.
Well, I'm just -- I'll start, then I'll ask again Jiwon to see if she has any thoughts on this. I mean I think that it's always that challenge of what's due to 1 versus the other. I think in -- if you look at the -- some of these effects on -- first of all, I mean, you've looked at lesion formation and that kind of stuff, we can tell there is an anti-inflammatory effect. But if you also look on these other outcome measures where people are improving, that seem to be disproportionately improving relative to other outcome measures. -- we would anticipate that some of that is due to its neuroprotective effect. But sometimes hard to tease that out. I don't know if I'll turn it over to Jiwon, if she has anything to add about them.
Agree with what Mike said, it's really hard to disentangle these effects. And in a way, we need to rely on some of these exploratory endpoints to get a better idea. And then, of course, the Phase III clinical trial data. But first of all, the trial population of caliper was a pretty inactive progressive MS older population. So we know that relapsing disease biology does not play a major role, although it plays a little bit of a role, as I showed in my presentation. And so yes, probably relapsing associated biology and the fact that we know vidofludimus does attenuate relapsing disease biology plays a portion of the effect we see on disability, yes, the fact that it's already a population in it enrich for mainly progressive disease biology suggests that probably at least a large portion of this effect is related to an effect on progressive disease biology or neuroprotection in this case.
And the other thing is this was an exploratory analysis, but when you look at the cell counts, which Again, it's not a perfect but one measure of a big component of progressive disease biology there was an effect. And so all of these things together, we never will know for sure, and it's very difficult to disentangle, but there is a good kind of underlying story there suggesting that at least a good proportion of that effect is related to a beneficial effect on progressive disease biology.
Thanks, Matt. Next one in the queue here is Eddie Hickman at Guggenheim.
That doesn't seem to work. So I jump to the next one, while we wait, which is William Wood at B. Riley.
Yes. I appreciate the extra color here today. Just thinking maybe directed towards both the management team and on the KOLs on the call, -- when thinking about the upcoming insurer readout with the discussions surrounding how progressive is essentially underlaid below the relapsing disease states, what might the KOLs be looking for from the insurer readouts that would really sort of support or point to this progressive disease benefit. And then maybe could the management team just remind us what potentially progressive end points you might be looking at ENSURE, whether that's sales or pearls might be looking at within that, that can give us sort of a better idea on the dual relapsing and progressive benefit here.
Well, so I mean, do you want to start? And then I'll join.
Yes. So I mean, I think it's kind of similar to what we just discussed with the Caliper study. It will be difficult to clearly disentangle these effects. And this gets to kind of 1 of the points I made in the slides that -- it's actually really difficult to measure definitively some of these effects on specific disease processes.
Having said that, though, if there is a clear effect on relapses and other measures reflecting relapsing disease activity and then progression as well as other measures, this tells us a story. We may look at things like relative effect on relapsing associated biology. And if there is a greater effect than we would expect on progressive disease biology measures, would be one piece that would suggest that there is an additional neuroprotective effect.
But then again, using some of these paraclinical biomarkers will be really important. And yes, they are exploratory measures. But together, they would be able to tell us this convincing story of what we are seeing. So it would include things like looking at Pearl cells as well as combinations of some of these fluid biomarkers.
We're in, does it address all your questions?
Yes.
Great. I have 2 questions here that came in, in writing from BubenPacaiapan and Aaron Welch over at Roth First 1 was the largest clinical actionable gap today, patients progressing despite ocrelizumab, patients unsuitable for immunosuppression or patients with nonactive disease. -- which group would you prioritize for vidofludimus and would you envision it replacing existing treatment or being added to it?
I can just make a commentation with nonactive disease are subgroup of ocrelizumab ocrelizumab-treated patients who progress because, I mean, now we have a lot of -- the treatment with anti-CD20 created a lot non-active progressive MS. So -- but I leave to the Jiwon to answer this question.
And like uropasaid, the nonactive patients are within that #1 category, but it's the more progressing independent of relapsing activity. And it's a huge proportion of people with MS, what you move closely enough.
All right. Then the second question is with fenebrutinib, having demonstrated noninferiority to ocrelizumab and FentrepiD. What would make a neurologist choose vidofludimus if both were available, better disability outcomes, a differentiated safety profile or benefit in a population competitors do not adequately serve, sorry.
I can say all of the above. But Jason actually pointed this out in his slides, but one of the criticisms of the fentepiD study is that fenebrutinib was tested in a non-inferiority way to ocrelizumab. And many people -- many clinicians think the benefit of ocrelizumab in PPMS is entirely related to its extreme benefit on relaxing associated activity.
So there -- in the field, there clearly is this need for a treatment that more definitively addresses progression in really nonactive people with progressive MS. And so in this trial, if the benefit is showed, that would be unique. And so it would be a bit of a unique niche in comparison to what fenebrutinib has shown, partly because of the trial design that was used with fenebrutinib.
And this notion in the field that ocrelizumab is probably not that effective on any components of progressive disease biology. It just really helps to shut down relapsing disease activity and people think the benefit in PPMS of ocrelizumab is really people who have ongoing relapsing disease biology. So should vetofludimus show a benefit in non-active SPMS and PPMS this is a unique niche. And so that would be a differentiating efficacy point. And then safety will be key as well.
There were some safety signals that have emerged with fenebrutinib, including this imbalance in deaths and this question about suicide. And so far, the safety data look good here, and obviously, we'll need to be controlled and Phase III clinical trials, but safety would be a big differentiating piece as well, particularly, again, in nonactive progressive patients that tend to be older, have more comorbidities, and therefore, we have more concerns about safety.
Yes. And then the last point I would just make from a general commercial perspective, similar to the relapsing of our market, we have to remember that progressive disease won't be a one size fits all. It won't be a 1 winner take all market, right? This is a large market of very little approved therapies today. There is approximately over 300,000 diagnosed patients collectively with SPMS and PPMS across both the United States and Europe. And so and as I've highlighted in my slides, we believe if you just extrapolate current net pricing today that this is upwards of a $15-plus billion market.
And so just carving out a significant, say, 25% of that market would be meaningful, meaningful upside in terms of peak sales for Vetoflutamis calcium. So again, I think Dr. O was very elect in her answer about the clear differentiation around the patient population and how that may play out in a commercial setting. I just wanted to remind people, again, that this is a huge market.
And if we can show continued success with vetoludimus calcium in this population and replicate some of the data we've generated to date, specifically on safety and tolerability, my belief has always been that this product will become the cornerstone of care in progressive disease.
Thank you, everyone. Next 1 in the queue here is Fozia Ahmed at Brookline.
Thank you for the wonderful event. My question is if you could share Dr. Oh your thoughts on the cells and pearls. -- what would it take for either to move from a mechanistic biomarker to something regulatory accept as supportive evidence of neuroprotection? And how reliable you can each be quantified across sites in a multicenter trial Additionally, do we have automated detection markets mature in app and in place for a pareto studies?
Thanks for the question. I wish I knew the answer to that, how to convince regulators that we should use imaging measures as endpoints in clinical trials. And I think the safe answer is that it probably will need validation in a number of contemporary trials showing a clear link to the disability endpoints that we are focused on. However, I know Maria Pia for many, many, many years, has been trying to get regulators to accept even GAD lesions as a measure of relapsing disease biology and -- it has been a really tough kind of obstacle to get over. However, on a positive note, again, given that the International Clinical Trials Committee aware of this and really pushing and getting regulators on board in these early discussions, and that's what that road map paper that I referred to was talking about.
I'm confident in the coming years that there will be a change where there will be an acceptance of multimodal composite endpoints. But it has been a challenging game to date and extremely frustrating I have to say, from a clinician and scientist standpoint just because we are very convinced that these measures are reflecting biologies we think they are, but the regulators seem to have a different mindset about that. But I think, hopefully, things will change.
Yes. And if I can add something, it will be easier in the future because modern clinical trials are including these measures. So it will be possible to run some post-hoc analysis to try to better understand their link with clinical measures to convince regulators to accept them.
And then just Fazio, getting to your other point about automated methods. So cell detection is automated, and it's mainly done by Nurr1 and so this seems very reliable and uses just conventional clinical sequences are actually obtained even in clinical routine. So you just need T1 and T2 weighted MRI sequences that are reliably obtained on the same patient.
With PRLs, there's much more of a consensus emerging about what sequences can be used to detect them. And again, in clinical trial settings, they're done by NeuroRx, and it is by visual inspection by people who have been trained and there's these consensus statements in the imaging field that guides the detection of PRLs. So overall, it seems relatively reliable.
We've done some internal studies about this, an intrarater agreement tends to be very high. especially with when you're using an organization like NeuroRx, that's very experienced with this, this is likely something that's a pretty reliable measure to detect similar to gas lesions.
Thank you. I would take 1 last question here, and then I think we close the call to be mindful of everyone's scheduled. So we have Yanyan Imogen over from the Kantar team asking in the chat. Thanks for all the insights and highlighting the needs of this very underserved group of patients Caligus effect size was similar to Hercules, Oratorio, and expand relapses excluded given that caliber is a Phase II study, could you walk through key differences and baseline characteristics that may have made the selected patient populations more difficult to treat versus other studies in addition to inactive older population that Dr. Mentioned? And could you share how you are thinking about Phase II to Phase III translatability?
Okay. If I can start answering this question. the caliper was a Phase II study. So it was not powered to see an effect on visibility. And it was -- the primary outcome was visibility, 200 patients per hour are a very small number. So -- it was quite the miracle that we saw this effect on clinical endpoint. So this is also a plus of the caliper study to have highlighted some effect on clinical endpoints while the sample size was so small. So this is very reassuring and the characteristical Phase III study is to be powered on a clinical endpoint. So basically to be much larger and much more power to see such an effect as significant.
I think that captures it. In terms of translatability, we use you're seeing effects on the same clinical endpoints you're using in your Phase III study, that's pretty encouraging translatability, we're just going to power them appropriately and be able to assess them in a way that should allow us to see a statistically significant effect at a meaningful threshold.
Great. Thank you so much for all the questions. This concludes our Q&A session. Erik, back to you for closing remarks.
Great. Thank you. I think in conclusion, when I think about whether or not to invest resources in a big question. I think about is there value to be created across kind of 3 pillars. One is, is there value in the science? Are we able to advance our understanding of the basic scientific questions at play. Second, -- or is there value to the patient community, meaning is there an unmet need?
And third, is there value capture potential for the company to recoup its investments in that? And I think that's my frame that I use to evaluate these types of questions. because these are ultimately quite expensive things to embark upon. But as I've thought about looking at various questions of that nature across my career, when I look at PROTECT MS in this study, -- it is extraordinarily clear that there's tremendous value across all of those ways of thinking about it. to be able to further our understanding of the biological underpinnings of progressive disease through the study and the role of NER 1 in having an impact -- that is a massive opportunity to advance our understanding of progressive MS and NRI.
For the value to patients, we've heard a lot about that today, but this is the largest unmet need in the MS patient community. -- and such an opportunity for us to really raise the bar of what's possible in the care of people living with this disease.
And then finally, Jason outlined -- this is a large and probably the fastest-growing market segment within MS Conservatively, this market is worth about $10 billion in the U.S. alone.
And so when I think about this from, do we have the possibility if we succeed to recoup the significant investments that we'll make here, I think I feel very comfortable about that and our ability to advance and create value for ourselves and our shareholders. And so across that spectrum, I could not be more excited to be initiating the PROTECT MS study to be advancing care to be running the first truly modern progressive MS study and to really be doing it hand-in-hand with such great collaborators in the community such as Maria Pia and Jiwon who've joined us on this call.
So with that, I'm going to wrap this and I would -- but before I do, I want to really extend a heart fall. Thank you to Maria Pia and Jiwon. Thank you so much for joining us and lending your expertise and your voice, not only on this call but behind the scenes in terms of really shaping our thinking and the approach to this study.
Of course, I'd like to thank my colleagues, hello, Mike, Jason and Jessica as well for all of your extraordinary work to prepare for this -- and maybe most importantly, thank you for those who've tuned in and your interest in what we're doing here because it's really important work. So thank you. If there's any further questions, please don't hesitate to reach out. We'll get back to you via writing and we look forward to getting the study off the ground as soon as we can reading out those ENSURE studies, don't let's not forget about those right around the corner and ultimately getting vidofludimus calcium to the patients who can benefit from it.
Thanks so much again. This concludes our event today. Thank you for joining, and you may now disconnect. Bye-bye.
Immunic, Inc. — Special Call - Immunic, Inc.
Immunic, Inc. — Special Call - Immunic, Inc.
1. Management Discussion
All right. Good morning to everyone on our webinar today, and welcome to Immunic virtual R&D Day focusing on our relapsing and development program with vidofludimus calcium. My name is Jessica Breu, Vice President, Investor Relations and Communications at Immunic, and I will be the moderator for today's webinar.
In the beginning, a few organizational remarks.
[Operator Instructions] and this event is being recorded.
[Operator Instructions]
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events.
Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.
Now let's turn to what we will actually focus on today. First of all, I'm very pleased that 2 internationally renowned MS experts will be speaking during today's event Dr. Amit Bar-Or from the University of Pennsylvania and Dr. Stephen Krieger from the Mount Sinai Hospital in New York.
Moreover, we will have members of the Immunic management team presenting, including Erik Lundgren, CEO; Dr. Mike Panzara, CMO; Dr. Hella Kohlhof, CSO; and Jason Tardio, President and COO. Our event today will focus on the status quo and future potential of our late-stage clinical asset with vidofludimus calcium for the treatment of relapsing MS. Our team will share mod of action, preclinical, clinical and commercial positioning insights on the potential of how Vidofludimus Calcium's differentiated approach could reshape the treatment for patients with Relapsing MS. Dr. Bar-Or and Krieger will provide expert perspectives on the MS patient journey, current treatment paradigms and unmet medical needs.
Now I would like to turn the call over to our CEO, Erik Lundgren, to take the presentation off, Erik?
Great. Thank you, Jessica, and thank you, everyone, for joining us. Good morning. I'm Erik Lundgren, the CEO of Immunic, and I'm thrilled to be with all of you here today. Thank you so much for your interest in our story. So Jessica, if you could just push on to the next slide, I'll be very quick so we can get into the exciting science here this morning. But just to set the stage, we are at an incredibly exciting and important pivot point in the company's history where we're really moving towards developing a fully integrated MS-focused company.
And as you'll hear throughout the session, we're right on the precipice of unblinding 2 pivotal Phase III studies that we hope will create a path for us to advance our lead asset, vidofludimus calcium into relapsing MS, so that we can address some significant remaining unmet needs in the MS community and needs that are faced by people living with MS on a daily basis. so as you sort of frame the conversation to follow, we are going to really focus in on that near-term inflection and catalyst point in relapsing MS. Keep in the back of your minds, we're not going to spend much time at all today on this, but another huge part of the value proposition for Immunic and for vidofludimus calcium sits in a potential progressive MS population with data to come. And in fact, I'll tease at the end of this a little bit of opportunities where we're going to have to share that story more in a more fulsome way with this community in a few weeks.
But the other pieces I'd love to just stress here is this pivot point of the company itself. We're really poised to build an MS-focused company full of executives and team members who have been in the field who care deeply about and and deeply understand the plight of people living with this disease and are really committed and passionate about transforming care in MS. That's really where we're focused. And we think we've got the right asset to do it. We've got the right capital structure to support it, and we've got the right momentum in our hiring practices to build that organization to take us into this new era for the company.
And finally, you're going to hear a red thread throughout all of these conversations that are principal posture right now in addition to driving our programs is listening. Really focusing on listening to the people who treat MS every day and the people who live with MS every day so that we're understanding what it is that needs to be developed so that we can take on the remaining unmet needs, which are significant.
Next slide, please, Jessica. So you can see highlighted in green, where we're going to focus a lot of our conversation today. That is on the relapsing program really anchored by our 2 Phase III studies, the ENSURE-1 and the ENSURE-2 studies, as you'll hear throughout, these are fully enrolled and we are tracking towards reading these out by the end of this year. So well on track there, much more detail to come. worth popping down to see the Phase II EMPhASIS study as well, which Dr. Panzara will go through some of the highlights of that study to, sort of, set the stage for what we can hope to see towards the end of the year.
Next slide, please, Jessica. And finally, just before we get into the science, just a few words on the market itself. The headline here is that MS is a large and growing market with significant remaining unmet need. From a market perspective, it is large. Globally, it's a $30 billion market -- or nearly a $30 billion market in the U.S., about a $17 billion market today, growing at about 7% annually. It's a market that recognizes and rewards innovation. And you can see that in the fact that there's been over 11 blockbuster therapies developed in MS over the last 25 years.
Maybe the most important piece to highlight here is it's a large and heterogeneous patient population with -- dealing with a chronic disease. And so what patients need at various points along their journey changes, and what that results in is the need for diverse sets of therapeutic options, unique mechanisms of action and the potential to address a wide range of needs over time.
So this is not a winner-take-all market. It's a market where we want to really tap into the needs of people living with MS, be aggressive in our development posture so that we're meeting and exceeding those needs and if we do so, it's a market that will value the innovation that we can deliver and ultimately, we'll see that rewarded in how the company can grow from that.
So with that, it's my immense pleasure to turn the stage over to the first of our guest speakers, Dr. Amit Bar-Or. Amit holds the Melissa and Paul Anderson president's Distinguished Chair at the University of Pennsylvania. And he -- there he directs the center for neuro-inflammation and experimental therapeutics and serves as the Chief of the division for MS and related disorders.
Dr. Bar-Or's research focuses on neuroimmune health and central nervous system inflammatory diseases. He runs a cellular and molecular neuroimmunology lab directed at understanding general principles of immune regulation and immune neural interactions and their contributions to inflammation, injury and repair of the human central nervous system.
Following an undergraduate degree at McMaster University, Amit earned his medical degree at McGill University in Montreal, Dr. Bar-Or has published over 400 peer-reviewed publications and has led multiple national and international abortive research initiatives. Thank you, Amit, for joining us, and I'll turn over to you.
Thanks, Erik. First, let me just confirm that you can both see the screen with the presentation and hear me.
We can.
Yes, we can.
Perfect. Perfect. Thanks for the kind introduction, Erik. And hello, everybody. Pleasure to be here and follow on Eric's background presentation and to tell you about targeting novel mechanisms to address the unmet needs in terms of the clinical context. And this is really going to end up leading to the biological basis by which we think vidofludimus calcium may offer some very unique advantages in relapsing MS with a focus here, but as Erik has already alluded to, in the context of protection and repair throughout the spectrum by MS. And so to do that, I'm going to start by presenting a very simplified model of MS immune pathophysiology. I'll try to avoid jargon and really only highlight the key points.
So it's not about too much immunology jargon to content with, but use that as a basis for commenting about some evolution in our concept of the clinical spectrum of MS. You'll hear more about this from Dr. Krieger, but I will introduce these terms of raw relapse associated worsening and PIRA, Progression Independent of Relapse Activity, and try to talk about some of the biological underpinnings as a way of them providing the framework for thinking about the mechanism of action of vidofludimus calcium.
So the unmet needs and the model promising targets is what we're really going to be segueing into to them deal with the biology in particular, of the Nurr1 pathway with a focus on trying to protect and support repair from ongoing injury throughout the MS process. And in the context of vidofludimus calcium in particular, the attraction of having potential for dual mechanism of action, both activating the Nurr1 pathway, but also selectively inhibiting the DHODH enzyme where we have a precedent in the MS field of an effective therapy that does so teriflunomide limiting relapsing disease activity as well as progression of disability.
So we'll start with a simplified model, and it's a very simple sort of 3 compartment concept of many, if not all of you, I'm sure have seen before, the lower right is the central nervous system, the target NMS separated by barriers for the immune system. We think of immune cells in the periphery outside of the CNS getting activated, upregulating molecules that enable them to more efficiently engage and cross the barrier and then get reactivated within the central nervous system compartment and bring to bear on the tissue.
Historically, for many years, for decades, MS had been thought of as a T-cell mediated disease, very much driven by most commonly used animal modeling in experimental autoimmune encephalomyelitis, but really our thinking has evolved importantly, particularly with the selective targeting of B cells with anti-CD20 therapies that really has helped us understand that it's not just about T-cells, it's about B cells and T-cells and very importantly, interactions between B cells and T cells in the periphery that are thought to drive the relapsing aspect of the MS. And then within the central nervous system, compartmentalization of processes that include almost certainly both inflammation and degeneration.
And the inflammation is thought to be driven by the reaction and the participation of brain cells, glia cells, in particular, microglia and astrocytes and infiltrating immune cells, principally B cells as well as T cells where the interactions between immune cells and immune cells as well as immune brain interactions are almost certainly contributing to the ongoing progressive injury that manifests clinically with progression of disability independent of relapsing activity, again, highlighting here the involvement of the brain cells, the microglia and the astrocytes.
Also as a side note, I think all of you will appreciate that there's been a resurgence of interest in Epstein-Barr virus now recognized clearly as an important necessary but insufficient element in developing MS. And more and more data interestingly coming out in high-profile papers to suggest that EBV may involve not just in the initial triggering of the disease, but also potentially in proposition with strong data suggesting involvement in relapsing disease, but also the suggestion that within the there may be propagation of that compartmentalized inflammation and injury.
The reason I point that out is because if a drug also has some antiviral properties, that may be an added advantage, and it turns out that this class of medication seems to have at least a component of that. Now looking a little bit about the clinical spectrum and providing a backdrop for again what Dr. Krieger will go into in greater detail. This would be the typical profile. If you look at disability or neurological dysfunction on the y-axis and time on the x-axis, most people with the mass present with bouts of disability that comes and goes in the context of the relapsing and remitting aspect, but then many, most of whom, end up with some aspect of progression independent of relapses.
So these events here are considered relapse associated were sitting. Some I'm getting worse from a relapse but not remitting completely. And this can also happen later in the disease, but eventually abates. And PIRA, Progression Independent of Relapse Activity, is represented as this little segment that may occur between relapses and then eventually without appreciating any relapses per se. So these are terms, they're not biological constructs, they're concepts that we try to identify people based on their clinical presentation.
We're interested in better understanding the underlying biology if we're going to set the stage for thinking of therapeutic targets. And the point to make, and again, Dr. Krieger will highlight this, I think, elegantly. The manifestation clinically doesn't necessarily capture the underlying biologies, which are clearly present largely under the surface. And we've come to realize that it's not as though someone with relapsing a mess magically when they transition into secondary progressive MS rather with these biologies overlap over decades of the MS process. And it really is about the clinical threshold.
If you had the clinical threshold set there, the shaded area would be subclinical. You consider this person as having relapsing-remitting MS onset and secondary progressive MS. But if you had an individual whose threshold was here, then clinically, they would no longer look like RMS to SPMS, but rather primary progressive MS. So this is a very quick way of trying to capture the evolution conceptually in the field that we recognize MSSP spectrum where these different clinical phenotypes represent people who clinically manifest differently, but all of whom harbor under the surface, both the biologies of relapsing and progressive type of processes.
And this is another way of recapitulating the notion of the overlap in gray, the left side of triangle focuses on relapsed biology and its manifestations, including the imaging. The lower right is CNS compartmentalized inflammation and degeneration. And you can see here that they overlap by decades, the predominant process changes over time. And this, of course, from a clinical expression standpoint is also going to be influenced by issues of repair capacity compensatory mechanisms and the reserve, all of which diminish over time and in parallel to that along the same timeline, increasing influence of immune senescence, inflammation comorbidities and so on and so forth.
In the context of, sort of, a biological framework, we can think of what we currently have and what remain as unmet clinical needs. And this is just very quickly shown here. We've done a very good job as a field overall in limiting new relapsing disease activity. That's the green checkmark here. Although one notes that while we control relapses extremely well with the high efficacy therapies, we're increasingly appreciating that there's a safety signal that will grow over time as more and more people are exposed for longer and longer periods. We have not yet done much in terms of CNS compartmentalized inflammation and degeneration. And we certainly have not really done much at all in terms of supporting repair and protecting.
And probably, to some extent, we have a grapple on some of the comorbidities and trying to deal with them, but this, sort of, on the lower right, is still a plus/minus area of unmet need. So this is the framework of thinking in the clinical spectrum of the various aspects of unmet clinical need, and we'll be transitioned now to the last part of my presentation, which really hones in on vidofludimus calcium's mode of action, which starts with targeting Nurr1 to address aspects of protection and repair from ongoing injury.
This includes, as Erik highlighted, injury that take place in the context of an acute inflammatory event or relapsing biology. But again, as mentioned, and I think importantly, this is present throughout the spectrum, including subclinically and the progressive biology also would benefit from Nurr protection and supporting repair. And the potential impact then, which will set the stage for some of the discussion of this unique dual mode of action combining the Nurr1 activation with selective inhibition of DHODH.
So a few words on Nurr1, also known as NR-482 as a potential neuroprotective target in multiple sclerosis. It has been known over the years that Nurr1 plays a central role in terms of signaling in general neuronal health. As a transcription factor of the steroid nuclear home and receptor family, it regulates a variety of genes that are involved, starting with neuro development but always through to function and survival.
It provides protection at the level of energy metabolism, the mitochondria, but also neurotrophic signaling and when activated also supports resistance to inflammatory types of injury. As a target in MS, in particular, on one hand, identify that reduced peripheral neuron expression correlates with more aggressive relaxing disease, a higher relapse rate and EDSS change presumably the raw the relapse associated worsening, normalized during pregnancy, which is probably 1 of the biological reasons as to what happens in terms of limiting the MS activity just by virtue of the pregnant state.
But then importantly, within the central nervous system, higher levels of Nurr1 expression in pathology samples were associated with preserved density, supporting a potential for neuroprotective roles. And when one thinks of Nurr1 activation in the context of neurodegenerative disease processes, which of course, extend beyond MS, but are very relevant for MS, it's known biologically when activated to reduce neurotoxic mediator release from activated microglia astrocytes that I highlighted before, are considered now principal players in a chronically activated state in driving CNS compartmentalized processes and progressive disease.
It supports mitochondrial and reactive oxygen piece related defense mechanisms, particularly relevant in acute relapsing injury but also progressive injury and then induces neurotrophic factors of GDNF and BDNF, very important for supporting neurons and promotes gene expression profiles that are linked survival and normal functional neurals.
In the context more broadly in neurodegenerative diseases, of course, there are pathologic hallmarks that are shared across conditions, MS and otherwise. And that's something I think that will be an exciting prospect moving forward.
Segueing now to the DHODH aspect of vidofludimus calcium's mode of action. DHODH is known metabolic checkpoint and particularly relevant as one of the pathways for permitting synthesis involved in highly activated immune cells. So when you inhibit this pathway, you don't limit the capacity of cells to deal with [indiscernible] DNA synthesis entirely, but you kind of cut the edge off the more activated immune cells, which are the ones that would be expected to participate in autoimmune processes, including in MS. It is a key mitochondrial enzyme and it's highly expressed again in these particularly highly active rapidly dividing lymphocytes and resting lymphocytes, less depend on it, and therefore, inhibiting it is not going to affect the broad immune system capacity to protect us as part of the normal immune response.
And with colleagues, [indiscernible] and others were able to show biologically that teriflunomide as a DHODH inhibitor indeed kind of cuts the edge off the overly activated immune cells involved in disease. And this inhibition is particularly targeting cell start to be pathogenic in the context of MS relapsing disease activity. And as I alluded to earlier on, there's a certain aspect about DHODH inhibition that may limit viral responses, including RNA protein synthesis and that this may include EV, of course, therefore, may be important to consider as an add-in benefit given EBV's increasing implication.
And so I think overall, this is a really interesting context, where neural protection meets immune regulation. Nurr1 again, having both direct and indirect neuroprotective effects and DHODH targeting as a way of reducing the immune cell hyperactivation involved in the relapsing disease process. This is just a cartoon that recapitulates the 3 compartments and the capacity or the potential of unifies calcium to be acting on these different biologies in the different compartments, leading to better support for neuron survival as well as immune modulation, having, in my mind, relevance across the broad spectrum of MS in relapsing and through progressive disease.
So I'll stop here, and I think transition to the next speaker. Having set the stage, hopefully, for suggesting that a dual mode of action combining Neuron activation and selective inhibition of DHODH may be very attractive in the context of the MS spectrum. So I'm going to unshare here and pass the baton on.
Thank you very much, Amit. This is a wonderful was a wonderful overview. And actually, so on the MS biology and specifically on Nurr1 and the role of Nurr1 and DHODH in MS. And I will go on now and fill it with data. So I want to talk about vidofludimus calcium's mode of action on Nurr1 and on DHODH. And we know already that vidofludimus calcium has a unique dual mechanism approach to MS. Potentially, it's the only oral MS drug that is really addressing PIRA and ROW simultaneously. So vidofludimus calcium is a direct Nurr1 activator. It modulates the gene expression directly in neurons. It mediates neuroprotection and neuron survival, and it reduces the neurotoxicity of microglia astrocytes which indirectly supports neural survival again. Therefore, it targets neurodegeneration beyond the focal inflammation.
In addition, what we heard already is the Select DHODH inhibitor, which is wonderful because it selectively targets metabolically hyperactive T and B cells, and it reduces the focal inflammation, MRI lesions and reductions. And what we heard as well, it prevents reactivation of Epstein-Barr virus. Excellent. So as we said, it is a selective DHODH inhibitors. And actually, I'm pretty proud about this that is this with the a inhibitor in addition to the Nurr1 activation.
So it selectively inhibits DHODH, you see here in this table that it has a 50 of around 240 nanomolar. And I just put in teriflunomide as a comparison. Teriflunomide is not active on the right, DHODH. Vidofludimus is most active on the [indiscernible] DHODH. How does it come? Well, there is a thesis specificity for DHODH. And this is -- can be explained because these are completely different chemical structures. You see here on the right, we see the structure of vidofludimus and you see just for comparison reason, you see the structure of Teriflunomide. In addition to this, we know by vidofludimus does not inhibit kinases. And where Teriflunomide targets different kinases, PIM or PDGFR especially EGFR and EGF, our inhibition actually is known or is related to skin diseases, diarrhea and liver enzyme elevation.
Both of them are active and -- on DHODH and on high affinity immune cells. So vidofludimus you see here just with the abbreviation Vido and you see Teriflunomide, they both reduce hyperactive or high affinity immune cells due to the restriction of the needed permittance. And in addition to base, of course, the tax including calcium in different animal models, just an example here that vidofludimus reduces the disease score in an information-driven EAE model. So it's a select agile inhibitor.
But in addition, that's on the next slide. In addition, it's a potent Nurr1 activator. What is really important and relevant in MS biology and in neuroprotection? So I depicted here, the 3, I would say, most important cell types in MS. So we have microglia astrocytes and [indiscernible] and actually, Nurr1 is expressed in microglia and astrocytes and in neurons. And Nurr1 activation leads in the glia cells to a reduction of pro-inflammatory cytokines and nitrogen oxide and [indiscernible] as well. In neurons, there's a direct effect as well because when we hear activate Nurr1, we see a reduction of oxidative stress, we see an increase of neuronal survival and differentiation of dopaminergic neurotransmission and myelination.
So that means that Nurr1 activation is believed to be involved in holding neurodegeneration and visibility progression. And this is also, of course, supported by [indiscernible]. That's not just my idea, it's really supported by [indiscernible]. And yes, and we heard it already very nicely summarized and explained by Amit.
So next slide, please. Now we can, of course, just populate vidofludimus calcium is Nurr1 activator. But can we prove it? And yes, we can. That's great. And you see here in the center, actually, you see the proposed binding model of vidofludimus towards Nurr1 ligand binding domain. This is just a model. But we were able to show by using ITC and DSS, vidofludimus calcium shows direct and leveragable binding 201 protein. So on the left, you see the ITC and the demonstrated specific binding signal with an estimated association content of around 700 nanomer, which really supports from of largely relevant target engagement. On the right-hand side, you'll see GSF and that can also [indiscernible] assay, which independently confirmed the interaction to a statistically significant shift in 1 melting temperature versus DMSO control.
So together, these 2 complementary biophysical data strengthened the evidence that Nurr1 is a direct molecule target of the vidofludimus calcium. So now you can say, okay, fine, does it matter? Yes, matters. Nurr1 is a transcription factor and therefore, we looked into Nurr1 associated gene expression, which is modulated by vidofludimus calcium and you see here, we tested in astrocytic cells, in microglial cells and in neuronal cells.
And we look for PH and VMAT, which are 2 well-known and described direct target genes of Nurr1. And you see here that vidofludimus calcium increase the expression in the selected non-regulated gene in a dose-dependent manner. So that is, okay, we see gene expression modulation. Is there any impact on function. And yes, of course, there is otherwise I wouldn't talk to you. So vidofludimus calcium improved neural survival and it reduced injury under [indiscernible] condition. So here, we use TNF [indiscernible] model. So we incubated viable neurons with NFL [indiscernible], this is an apoptotic and [indiscernible] and necrotic stress signal year in cells undergo apoptosis.
And in the presence of vidofludimus, you see an improvement of the neural survival. This is actually depicted here in the middle where you see that in the presence of vidofludimus calcium in a dose-dependent manner, you see an improved neuronal survival. We did not only count just in neural cells here, but we looked as well for neuronal injury marker. And this is a well-known neuropen light chain, what is measured in clinical studies quite often. And here that, again, in a dose-dependent manner, you see a reduction of neuronal injury marker neurofilament light chain. So vidofludimus calcium was associated with a full serial survival and reduced neurofilament light chain release under these [indiscernible] stress conditions.
Next slide, please. Now you can say, okay, that's vidofludimus, because it is Nurr1 important here or is it just because of the DHODH inhibition. And we were able to demonstrate that really Nurr1 is required to mediate this neuronal survival here. So again, [indiscernible] is quite similar to the previous picture, where you're at in about cyclohexane, you see it in red, you have a decrease of the viability or the number of the living cells. And in the presence of vidofludimus, you see again the increase or a higher number of the living cells. That was performed with [indiscernible] cyclohexane, but we use as well an additional trigger here.
So we were able to demonstrate it with 6 OHDA, which is a model where it's more about oxidative and mitochondrial injury compared to extrinsic [indiscernible] signal and what you see on the left. So vidofludimus calcium is able to do it. Now is Nurr1 important here or not. And this can be seen now because here, we used crystal-mediated Nurr1 lockout.
And you see it that when you have neurons, which unlocks out for Nurr1, then vidofludimus calcium is no longer able to improve the viability and the number of living cells in this model. So vidofludimus associated improved neuro survival really requires Nurr1.
Next one, please. Of course, I talked about microglia. Microglia super important because they drive inflammation in the brain as well. So we were interested in the role of vidofludimus calcium on neural viability and the neuroinflammatory condition. And therefore, we performed the neuron microglia co-cultures here. So we co-cultured microglia and neurons then stimulated the microglia to produce pro-inflammatory cytokine and see just on the graph on the left that the neurons are undergoing apoptosis in the presence of vidofludimus, they have a higher -- we see again a higher number of neuron stuff.
So in the middle, you see when you add LTS into from [indiscernible], you see a reduction of living cells of the -- in this case, human saline [indiscernible] cells. And when you then add in the presence of vidofludimus, you have an improved survival ability. Of course, we wanted to know is a really mediated by microglia or is it just toxicity that is driven by LTS and [indiscernible] gamma. Therefore, we added the control experiment what you see on the right that no LTS and grammar [indiscernible] don't do any harm to neuron alone. So vidofludimus calcium was associated with increased neural viability in inflammatory coculture.
Now it comes to animal models. Does vidofludimus calcium work in animals? Yes, of course, it does. We did several EAE models and we were able to demonstrate that vidofludimus calcium reduced disease severity in EAE model. Now we know in a prophylactic setting and therapeutic setting. And of course, we all know that EAE models are mainly inflammatory driven. So it could be that DHODH inhibitors work there. And indeed, works there. That's fine. Vidofludimus works there. And we use these models because we are interested in investigating the impact of vidofludimus in these models on Nurr1 and we were able to do it.
So on the next slide, you see here that vidofludimus calcium model related Nurr1 related gene expression in the CNS of the mice in these EAE model. We investigated the brain and the spinal cord, and we looked into the prophylactic and into the therapeutic tapping of these animal models. And you see here in the brain on the left that in the presence of vidofludimus calcium, we see an increase of Nurr1 itself. So there seem to be an auto regulation. So we have higher levels of Nurr1 in the brain of these animals. And we look as well for Tapityrosine hydroxylase, which is a well-described primary targeting of Nurr1.
So in the brain, we saw Nurr1 upregulation and TH upregulation by vidofludimus calcium. And we look as well into the spinal cord. And actually in the spinal cord, we focused more on the detoxiccation of super [indiscernible] radicals by SOD upregulation and we looked into ATP production in principle via the upregulation of [indiscernible]. So vidofludimus calcium treatment was associated with the modulation of Nurr1 regulators related gene expression in CNS tissue in both the prophylactic and the therapeutic inflammation-driven EAE settings.
And we look for functions while we were interested in proteins in the plasma, if we can measure it looks for BDNF, which is brain-derived neurotrophic factor, and you see that even in the plus more this, we can demonstrate that we have a higher exposure or a higher production of BDNF and the plasma of these -- vidofludimus calcium treated mice, EAE mice and here, we, again, we looked for neurofilament light levels, which will decrease under the treatment of the vidofludimus calcium.
Okay. So now you can say if every DHODH inhibitor and Nurr1 agonist, and I would clearly say no. So there was a publication from [indiscernible] in 2023. They described it already, but I'm pretty sure that you guys are super interested in Teriflunomide because it's approved for MS. So we looked into this. And you see again here, ITC testing, you DFS testing. We were able -- you see again for vidofludimus calcium. There is a binding signal detected, of course, for vidofludimus calcium on Nurr1. And we did under the same conditions we have for Teriflunomide and actually, there's no proper curve, so we don't see any natural binding here in ITC. We did it as well in DSF, being just a different assay system. And again, and the curious calcium in users a temperature shift, melting temperature shift, which indicates the binding here, whereas Teriflunomide does not.
So that means, okay, there's -- most likely, there is no binding of Teriflunomide to Nurr1, but it could mean maybe there's an indirect effect towards Nurr1 that can't be measured via the direct interaction. So we looked as well for the function. And I told already about neuronal survival and [indiscernible] stress conditions, and we did the same experiment on the next slide. It's the same experiment in the presence of Teriflunomide. And what you clearly see here is that vidofludimus calcium improves the neuronal survival and apoptotic stress conditions, whereas on the right Teriflunomide did not.
So in this test system, Teriflunomide did not significant improve survival of neuronal cells. Another hint that it's really not directing Nurr1, it's not binding, and it's not promoting any survival functions in neuronal cells. So to summarize everything, we can show that vidofludimus calcium activation and selective inhibits DHODH. So with Nurr1 activation, it's improving the survival of neurons and it's reducing neurotoxic microglial activation. DHODH inhibition selectively targets only metabolically active TMB cells and with having DHODH inhibition, vidofludimus calcium is able to inhibit the EBV associated B-cell responses. Thank you.
Great. Thank you, Hella. And good afternoon, everybody. I'm Mike Panzara, the Chief Medical Officer. Mike, it's a great pleasure to be here with you today to talk about our efforts in relapsing multiple sclerosis, focusing on the ENSURE program. Next slide, please. So I think in the 25 years, been doing this drug development and academics and MS focus before that as neurologists in these patients. The way things have changed over that time in the treatment of multiple sclerosis has been just remarkable. And I think Steven and meet my colleagues in the space would agree. It's been quite what has been accomplished and what is available for patients today. We couldn't have even thought about back then. But if you -- it makes you feel pretty good about what we've all accomplished.
But it really don't want to feel really good. Just listening to this patient-focused drug development meeting that happened to FDA at the end of last year that despite therapy, 20-plus approved DMTs in this space, there are enormous unmet need that exist just listening to the people with MS talk about how while their doctors are telling them they're doing great, they're not having relapses. The MRI regions are not detectable.
They just feel like they're getting worse. They just running out of options because of their age for a variety of reasons, and they're looking for something new. And this is truly a remarkable revelation certainly, when I watched this and really speaks to why vidofludimus calcium is so important and has great potential to help many of these patients.
Next slide, please. I mean you've already heard about the biology. You've already heard about how the dual mechanism of action leads to potential to treat different aspects of the disease. But the effects would be anticipated to address both these important elements of disease as it needs outlined for you. And that's what the next therapies really should be doing. We should be thinking about how do we tackle not just how we reduce those relapses, but how do we treat this underlying progression of disease, this biology that is a neat laid out begins right at the earliest diagnosis of the disease, even if the threshold of visible activity is not there. It's happening, it's moving along, and it needs to be addressed.
Next slide, please. So as we go into Immunic using vidofludimus calcium in relapsing MS. The first -- the Phase II study here is showing the EMPhASIS study. This is a study looking at a double-blind study focused on relapsing MS, looking as is often the case in MS development programs, lesion formation. Looking at whether vidofludimus calcium when given to patients with early active multiple sclerosis, whether there can be leasing reduction because this is truly really one of the best predictors of whether a drug has the potential to be successful in Phase III using this important MRI biomarker.
In the next slide, what we saw was very clear. There was a robust lesion reduction over 24 weeks in this patient population using cumulative active lesions as well as combined unique lesions as well as [indiscernible] enhancing lesions. And you can see that both the 30- and 45-milligram dose were quite effective versus placebo with a very minimal effect of a 10-milligram dose. So with -- this led to the -- some of the initial decision that there would be great potential of this from relapsing MS.
When one looks at relapse outcome, next slide, you can also see that there was an encouraging effect on relapse. What you're looking at here is the time to first relapse, this is a capital curve. What you're seeing is that it trended towards significance, a 42% reduction in the risk of relapse. And you can see the proportions relapsing there. And this is for the 30-milligram dose, so there wasn't much difference 45 milligram, just similar to the MRI, there was no difference. And you're starting to see an effect in 6 to 8 weeks. So with the Garion-enhancing lesion results as well as this result on an approvable end point. This led to the design of the ENSURE study. But very importantly also, there is a very favorable safety profile, and that's what you're seeing here. There is really no signal in this cohort of injury, no indication of bone marrow suppression or GI side effects.
The drug is a very short half-life. And when one looks at this in the context of currently 3,500 patients that have been exposed to vidofludimus calcium over 6.5 years with the longest patients now passed 6.5 years in open-label studies, this seems very encouraging in terms of the benefit risk proceeding into a Phase III study.
Now many of these patients ended up going into an open-label extension study, and that's what you're seeing on the next slide. And what's really encouraging there is that the study is currently ongoing. We've -- the retention rate is extremely high. And you can see that there is this stable low progression of patients with continued open-label treatment with low description rate. Now acknowledging it's open to open-label study. But nonetheless, when 1 sees that patients are remaining in the study and continuing on treatment with a favorable safety and tolerability profile, which is extremely encouraging as we head into Phase III studies. So now [indiscernible] where, as was noted earlier, we are approaching the end of our Phase III studies. We had these are the NSR Phase III studies. They've now been going on for several years. And these are the pivotal studies designed to confirm the immunomodulatory effect. So specifically, the relapse reduction effect.
Now to do this study, it was very important to is very important to focus on the safety of patients, and this is a placebo-controlled study. And one of the key elements of this study was to -- even though we were doing a placebo-controlled study, we need to make sure patients were kept safe. And the way that was done is that these 2 large Phase III studies allowed patients on placebo or active treatment in the setting of a relapse receive active treatment as a rescue.
That allows us to measure the relapse effect, which was the whole purpose of this study to be able to detect whether the vidofludimus calcium is a meaningful effect of relapse reduction, which is a clinically meaningful endpoint as well as associated endpoints. But what it does do it could cloud our ability to see an effect on disability progression, namely the time or the slowing of 12 or 24 weeks sustained confirmed disability worsening. But that -- but nonetheless, this -- we anticipate that the endpoint here, and we are aligned with the endpoints with the regulatory authorities as we proceed such that if we saw an effect on time to relapse or risk reduction, that would pave the way to a U.S. submission.
And we're likewise encouraged by the fact there was a interim analysis in October 2024, where it was a futility analysis where the independent data safety monitor committee recommended that the study continue unchanged. So all this is very encouraging as we move forward.
Now the next slide shows you a bit about -- more about the study, and this is some new information here, where we really targeted in early active population. And we went to places in the world where we could find an early active patient population for placebo-controlled trials. On the right-hand side, you're seeing the distribution of clinical trial sites, most of them were in central and so you're up with some sites in Western Europe, U.S. and Canada. You can see the inclusion criteria in the right -- left, excuse me, again, targeting that population that we saw an effect on in our Phase II study in the EMPhASIS study, specifically looking for early active patients that had met the diagnosis of relapsing MS for the [indiscernible] criteria as well as the leveling criteria for active disease.
And when one looks at the next slide, which is actually the baseline characteristics, you can see this is exactly what we've achieved. We've recruited a very similar population and ENSURE to the EMPhASIS population. We have patients with similar age and gender as well as the distribution of [indiscernible].
And interestingly, about 50% of the patients have received a prior treatment. So we'll be able to see very nicely whether those who are naive to treatment versus those who received treatment, how vidofludimus does perform in those patients. But importantly, when one looks at the EMPhASIS study, the patient population there and the patient population and ENSURE and one figure does what we've seen an EMPhASIS encourage us about what we're going to see in ENSURE, it certainly does. This is about as close as you can get to confirmatory studies.
Now when we are deciding on endpoints, as I mentioned, time to first relapse is the endpoint for the reasons I've outlined, but we also include a variety of secondary endpoints that allow us to further understand the effect that the plus calcium has in patients with MS. And actually, in selecting those endpoints, you can see on the right, again, quotes from the patient-focused drug development meeting where the endpoints we selected are the endpoints that we believe based on this feedback, will be meaningful for people living with MS should we show an effect.
And that's mainly focused on the typical things like relapse as we've expected, including the ARR. But very importantly, novel endpoints such as net clinical benefit and looking at time to disability a 12-week confirmed disability improvement. We've been very encouraged in our phase 2 studies on progressive MS, which you'll hear about it another time, where we've seen patients who -- we just -- there are signals about not just slowing disability worsening, but improving certain patients improve on treatment.
And we are -- put that in our secondary endpoints at a high level to really confirm that this effect which would suggest some aspect of the biology that you heard about and then endpoints looking at whether patients are overall feeling better on treatment. And so -- and you can see here we've outlined that for you. So you can understand that the commitment here is not just to look at those endpoints that are so critical like relapse and disability but other endpoints that can tell us, are we addressing the needs that patients are telling us we need to address.
Next slide. So in summary, we are on track for pivotal readouts this year before year-end and focused on delivering NDA following those readouts. We have a program that in relapsing disease is about as derisked as it can be with a robust Phase II study and endpoints in Phase III that are comparable with alignment with the regulatory authorities and the precedent behind us on our endpoints. And that really gives us a clear path to submission upon a positive outcome later this year.
So with that, I want to turn the mic over to Stephen Krieger. Dr. Krieger, who's a Professor of Neurology [indiscernible] School of Medicine at Mount Sinai Hospital in New York. He graduated from Columbia College and received his medical degree from [indiscernible] and completed his residency and fellowship at Mount Sinai. Dr. Krieger has participated in numerous MS clinical trials and lectures internationally about MS with an EMPhASIS on emerging therapies in MS disease course, which you'll hear more about today. Dr. Krieger is best known for proposing a topographical model of MS and novel visualization of the MS clinical course. And it's my pleasure to turn it over to Stephen. Thank you.
Mike, I appreciate it. I hope I see my slides now. So this has been a great background about the science of our field and the science that has led to the development of vidofludimus calcium. What I'm going to do is step back a little bit and speak from the perspective of clinician, people in the field treating these patients and facing some of these unmet needs and thinking about what our goals of care are now moving forward. And I titled this the unmet need in relapsing MS has changed because the whole field of MS has changed. Our approach to relapsing disease is evolving. And even though -- in a sense, we have a real plethora of treatments available to us. This is not a solved problem.
And Mike alluded to the voice of the patient report from the MS society. I'm going to allude to it also, but it's honestly facing that voice in those perspectives that we're looking at every day, and I'm going to try to bring some context to that. And in intro, Mike mentioned the topographical model of MS. It's my life's work, and I'm going to summarize it for you in 1 minute to try to make it as relevant as possible to what we're facing in our practices and what the unmet needs are in our field.
You've heard a little bit about PIRA and RAW, and I'm sure you're familiar with it from looking at trials. But I want to put that in context of the disease course, and that's really what the topographical model intended to do. So when we think about lesions and MS, new T2 lesions, some of our main outcomes as you heard in our early trials in Phase II trials, lesions are often in the cord, the infratentorial compartment or the hemispheres of the brain. We compensate for lesions, but our ability to compensate is different depending on where those lesions are.
So lesions in the spinal cord in the optic nerve cause symptoms lesions like these in the hemispheres are often subclinical below the clinical threshold a useful measure in our trials for disease activity. But when lesions form in the spinal cord of the optic nerve, that causes a clinical event above the threshold there CIS first attack here, another one causing a relapse with recovery, but what you're seeing happening is just toehold that Dr. Bar-Or mentioned is declining. And as it does, it emerges above the threshold as PIRA, progression independent of new relapses, sometimes with relapse associated worsening super imposed. But as time passes, that threshold drops the brain atrophies and so much of the disease burden gets revealed above the threshold as PIRA, most of the disability that accumulates is progressive.
And even though we're here talking about relapsing forms of MS, this is happening early on in relapsing forms of the disease. And so the issue of treating MS early and trying to quiet down the disease topography, stop new lesions and relapses from forming is important, but it ultimately is trying to change the trajectory of disability as it forms.
In that way, controlling relapses is part of our treatment goal, but not the whole one. the perspective on our field began with treating relapses almost as an end in themselves. Now we can think of it as treating relapses as a way of shutting down acute inflammatory disease. That is something we've become very good at. as I'm sure all of you know, with the advent of high efficacy therapies in B-cell depleters, and I'm going to talk about that in a moment. But what that has revealed for us, in a sense, is PIRA. It is revealed for us that even though we can prevent relapses in lesions, declining reserve, neuroaxonal injury is contributing to that dropping threshold and the risk of disease accumulation.
That is not something that happens only late in the disease. Talking about relapsing MS, let's begin at the beginning. Our disability scale is the EDSS. The EDSS of 0 has been defined as normal for 40 years in our field. And when we did a study here in Mount Sinai looking at that a couple of years ago, we challenged our patients with more difficult physical paths harder than what we do on a conventional nerve them and found there are signs of weakness imbalance incoordination, fall risk right from the beginning of this disease, right, from EDSS 0. So we talk about the clinical threshold.
I really like Dr. Bar-Or's way of showing that you place the thresholds for different places, you can think of the disease course a little differently. I'm pointing out that even at the lowest, earliest level of this disease, we can look below that clinical threshold and find damage and here is some data to support that. PIRA, this gradual progression starts out early in the course of relapsing disease from this project from [indiscernible] and colleagues found that 8% of the cohort of relapsing MS had PIRA within 5 years. And 25% of them across the period of follow-up at PIRA. These are not people who are calling secondary progressive MS. This is people who are accumulating disability gradually even when we don't give it that nomenclature, and the sense of futility that, that nomenclature has often provided to people living with the disease.
The risk of PIRA causes a 26x higher risk of accumulating significant visibility and EDSS 6 is someone needing a came over the years that follow. And remember, people during their 30s. So meeting a [indiscernible] within years of diagnosis, is an unacceptable outcome that we're endeavoring to prevent. Mike Panzara pointed out this [indiscernible] Voice of the Patient report, which is what we're listening to in practice every day. Patients telling us that they're worsening even when we don't see new relapses or lesions, but they've stopped or changed their disease-modifying therapy because in one way or another, they're unsatisfied with it, either their disease is worsening or they're having side effects. That's the message we're being told. And when we look at large data sets, this was work done by my mentor, Fred Lublin using a massive data set that combines both the real world and clinical trial outcomes.
Here's what disability in MS looks like. This was published in brand a couple of years ago. In blue is PIRA progression, in teal are relapses associated worsening. In relapsing MS, there's both. In forms of MS that we conceptualize as progressive SPMS and PPMS it's all PIRA. But I want to point out to you that that's happening right from early on in the disease. So when we talk about relapsing MS, we're talking about both mechanisms that Dr. Bar-Or talked about, talking about both ways that disability can accumulate. How much can we do about this? So it is easy to look at our field and think with the advent of high efficacy therapies in general and B-cell depleters in particular, that this whole problem has been solved.
And in fact, the use of high efficacy therapies shows us the problem that was, in a sense, hiding in plain sight that PIRA continues to occur. So in OPRA, which is the oprolizumab versus INTERFERON pivotal trial from a decade ago, disability accumulated, of course, more in folks on INTERFERON and on ocrelizumab, most of that disability was PIRA in both groups, relapse associated worsening with small, even for the interferon-treated patients, Nonetheless, relapse associated worsening is attenuated by a high efficacy therapy that stops or relapses. PIRA, less so, PIRA was less responsive to treatment.
Now partly, that's because of how our high-efficacy therapies work. They work on inflammatory biology, do not working in the central nervous system, and they're not working to do any sort of restorative technique. And so PIRA is going to creep in even in the setting of keeping in my language, the disease topography flat because some of that disease topography is already forged. And if reserve is being lost and the threshold is dropping, simply preventing new relapses and lesions isn't going to stop it. We have had a huge influx of patients on to B-cell therapies over the past decade.
I mean it has been transformative for our field. But what that means is now I face patients every day who've been on B-cell depleters for 5 years or longer coming on 10 years. And what we're starting to appreciate is the cumulative consequence on the immune system of B cell depletion. When you knock out the emergence of new B cells and the maturation of these cells into plasma cells over years, circulating antibody levels drop and hypogammaglobulinemia kicks in. And so this one study looking at 20,000 patients across an aggregate of study found 11% of prevalence of hypogammaglobulinemia on patients on B-cell depleters. This has started to become a concern for us. And now when I talk to patients starting a B-cell depleter, I don't think that they're going to be honest to the rest of their lows. I say, think of this as a 5- to 10-year plan. And I think that is a way of curtailing some of that cumulative risk. But what that also means is all of the patients with relapsing MS have been on B-cell depleters for 5 to 10 years, are going to have to look to what happened after that 5- to 10-year plan.
We care about low immunoglobulins because there is emerging data that it does track with an increased risk of infection. It's a predictor. So this is a single looking at 238 patients treated with ocrelizumab for 6 years -- up to 6 years. the drop in immunoglobulin IgG started to happen on an annualized basis, and it did start to track with infections. So you see here the percentage of patients needing oral antibiotics, so relatively small but higher in the people who needed -- who had rather low immune module. Patients who needed [indiscernible] antibiotics, thankfully, this is a small number. But again, you see the risk is twice as high for people whose immune globulins have already started to drop. And patients with MS needing IV antibiotics is in a clinical trial. We would consider that a serious adverse event. I'm not admitting patients routinely for this. This is not something that we tolerate.
So if our treatments are starting to cause increased incidence of serious infections requiring things like IV antibiotics, this is a problem, and we're going to need to adapt as a field to that changing landscape. I'll point out here that age is a risk factor for increasing infections. And it was a risk factor here in this project and factored into the regression model.
But the other thing that's happening to our MS population is their aging -- we've done a great job with MS, and that means our population is going to live longer and longer into late adulthood and into their geriatric years. Our strategies have to evolve because we're not going to continue suppressing cell lines and people were 60, 70 and 80 years old. I'll take a step out of the B cell of leaders for a moment, even though that has really been a huge deal for our field and say that the first real transformation that happened now 15 years ago in MS was the advent of oral therapies. And when I got started in this field every day, patients taking injectables had say, doc, when are we going to get pills. And then we got pills and things didn't get simpler all of a sudden, they got more complicated.
And that's in part because of the legacy of our first oral agent for MS, which was fingolimod. And the S1P modulators brought with them a lot of potential side effects and adverse events and monitoring that had to happen upfront. It wasn't what the MS community was sort of expecting from having a pill. And I think that as we've now had pilled in various forms, prorates, S1P modulators, Teriflunomide and also oral cladribine over the last 15 years, we've gotten a sense of that complexity of some of our oral agents. With the fumarates, there are issues relating to GI tolerability and flexing. Our S1P modulators, now it's a whole class of them, still require a thoughtful consideration of cardiac comorbidities concern from macular edema, concern for infection, concern for liver issues. Taraflutamide has long been associated with alopecia as well as pregnancy and family planning concerns that, that has been an issue for the big cohort of MS patients or of child-bearing age and potential. And oral cladribine, which has now been out for about 5 years, inherited the concern for malignancies from its clinical trial campaign. And that has, in many ways, seriously curtailed its use here and abroad.
So there are issues to contend with, with oral agents, and side effects often carry more weight. This is also true in that NMS asset voice of the patient report, which I come back to here because it tells us something about why patients are happy or unhappy with their treatment. When you take into account the sort of MS community perspective, concerns that people have that the fundamentals of their disease aren't being addressed repair mechanisms and protection, stopping progression. These are not things that we can comfortably offer to patients now and they know it. And they're telling us. I think Mike's point that it's quite humbling listening to that voice of the patient report, I think that's good for industry to hear. We, on the clinician side, are hearing it every day.
So we know that these unmet needs really exist. The aging MS population and again, this post B-cell population. We had the B-cell influx. Now we're facing a B-cell Eflux that people are going to come off set strategy, need new treatment approaches. So thinking about the unmet needs in the disease and how they've changed, I'll wrap up here to say we need to continue to control visible disease, the above threshold manifestations, new lesions. We need to better control progression and we need to think beyond the immune system itself. We've had great success with the peripheral immune system. But MS is a disease of the central nervous system. We need things that act within the central nervous system to try to address some of those unmet needs.
And I'm not going to rehash what you've already heard in great detail from the people developing the agent. But this is why vidofludimus calcium has a niche that it could fill because it works on both a strategy that can address active inflammation and relapses. It works on a strategy at this point, untapped through NEURON modulation. And it is oral, it is simple. It doesn't require infusion centers, and that remains an advantage. So I'll stop there. I'll turn it over to Jason Tardio, who is going to take it from here, and thanks so much for having me joining today.
Excellent. Thank you so much, Dr. Krieger, and good afternoon. My name is Jason Tardio, the President and Chief Operating Officer here at Immunic. What I'd like to do is take all the information we've heard today, the science the biology, the preclinical data, the clinical data, the overview of unmet needs and translate that into what we believe can be a compelling commercial opportunity for vidofludimus calcium in relapsing MS. The main takeaway that I want to establish, and Erik alluded to this earlier, is that the relapsing MS market is a large dynamic market where treatment decisions are highly individualized and patients frequently move between therapies over the course of their disease and over the course of decades treated with disease-modifying therapies.
We believe that this creates multiple opportunities for differentiated therapy like beta plumes calcium during the course of a patient's overall journey. Next slide, please. As we heard today, despite having more than 20 proof of therapies, significant unmet needs remain. We see 3 in particular, right? PIRA, Progression Independent Relapse Activity. We know it begins early, it becomes increasingly important as the driver of disability over time. And I think most importantly, there's no medicines today directly influencing and impacting the neurodegenerative component of the disease that drives PIRA. We believe the vidofludimus calcium given its Nurr1 activation could do just that.
The second unmet need is safety. We know DMC's carry meaningful safety trade-offs. This includes serious infections like progressive multifocal leukoencephalopathy, increased risk malignancies, increased risk of pad and liver toxicity. And the safety considerations become increasingly important as patients age and accumulate comorbidities. And the third unmet need is tolerability. We just heard this for better premium. Side effects remain a significant reason why patients discontinue therapy.
And if patients discontinue therapy or is unable to take the therapy, they're not going to benefit for the potential efficacy of that respective therapy. In fact, in one real world study, upwards of 50% of patients on Gilenya and close to 70% of patients on TECFIDERA discontinued therapy due to tolerability issues. This is a real issue, and we'll talk about the importance of that to patients in just a moment. So despite tremendous innovation in MS and, there remains an opportunity for therapies that can deliver a better overall balance of disease control of safety and of tolerability.
Next slide, please. And that opportunity exists in a very large and growing market. The U.S. relapsing MS market is approximately $17 billion a day and is projected to grow to over $25 billion by the time we get into the 2030s. The anti-CD20 therapies have clearly become the largest class, representing about half the treated patients today. But it's important to note that the oral therapies continue to represent close to 30% of the market by patient share. So despite the success of the anti-CD20 class, there remains a substantial and durable preference for oral treatment. And we believe this creates a significant opportunity for innovation, specifically within the oral disease-modifying therapy class.
Next slide, please. If you all remember 1 slide from my presentation today, please remember this slide, the relapsing at this market is not a winner-take-all market, but rather as a dynamic market in which approximately 45,000 patients initiate therapy each year. Another 45,000 prescriptions are associated with patients switching off of therapy. And on top of that, even with 20-plus available therapies, there's approximately 125,000 diagnosed relapsing MS patients who are currently untreated. And switching isn't a failure of the market. It's a fundamental feature of just MS Journey and MS care. Patients initiate treatment, they switch treatment because of breakthrough disease, they switch treatment in terms of safety concerns, they switch treatment because they're having tolerability issues. And treatment strategy has evolved as patients get older, Dr. Krieger, again, just alluded to.
Importantly, there's not a single disease-modifying therapy that optimizes every attribute for every patient and every stage of disease that can stand decades. So vidofludimus calcium does not need to be the answer for every patient, but rather it needs to be a compelling answer for the right patient at multiple points along their journey.
Next slide, please. And that's particularly important because MS treatment is highly personalized. This is not a one-size-fits-all market. Physicians constantly balance disease severity, age, immune status, preferred route of administration and each patient's individual tolerance for risk when considering a therapy that's appropriate. At the same time, the prescribing community itself is highly heterogeneous. We heard from 2 KOL academic clinicians today. But MS specialist may approach treatment different than general neurologists. Some physicians about 40% favor an escalation approach, while about the other 60% favor earlier use of high efficacy therapies. And of course, prescriber can differ between general urologist, academic KOLs and individuals treating within a community setting. Commercially, that means there is not one single relapsing MS patient or 1 single prescribing algorithm, and differentiated therapy needs to offer a clear value proposition across identical patient segments and physician types, and we believe vidofludimus calcium has the potential to do just that.
Next slide, please. One assumption that's worth challenging is that MS treatment selection is simply an efficacy haerarchy. It is not -- when physicians were asked directly about attributes that matter most with selecting a disease modified therapy and MS, safety actually rank #1, slightly ahead of relapse reduction and reduction in disability progression. Of course, efficacy remains critically important, but physicians ultimately make a benefit risk decision, not an efficacy decision in isolation. And that is why we believe the totality of the vidofludimus calcium profile could be so important.
Next slide. And it shouldn't be surprised when you ask patients, the message becomes even more pronounced. Side effects were by far the largest driver of treatment preference accounting for more than half the relative importance patients assigned to attributes evaluated. It is important to remember that patients will live with EMS for decades and therefore, will be treated for decades with disease-modifying therapies. They obviously want disease control. But they also care to believe that a therapy that makes the therapy makes so feel the risks that they're accepting, how it affects their daily lives and how much burden the treatment places on them.
So safety, tolerability and convenience are not secondary attributes. They can be central to long-term treatment success in relapsing multiple sclerosis.
Next slide. And this brings us where we believe vidofludimus calcium will offer a compelling value proposition. We're not trying to build the value proposition around one single attribute. We're targeting the optimal balance across attributes that matter to both treating physicians and HCPs and to patients. First, the dual mechanism of action, potential neuroprotective effects through Nurr1 activation combined with [indiscernible] anti-inflammatory effects through selective DHODH inhibition. Second, safety. Based on the clinical experience to date, we believe telephones Houten has the potential to reduce some of the important safety concerns associated with currently marketed and potentially future DOTs, including hepatotoxicity, serious infections and lymphopenia.
Third, tolerability. We have observed a favorable tolerability profile to date with low rates of discontinuation due to adverse events and without many of the prominent tolerability and side effects that cause patients to discontinue currently marketed products, including GI flushing, alopecia related tolerability and others on some of the marketed products. And finally, once a day oral convenience, which reduces treatment burden for patients, for physicians, and for their offices.
Ultimately, we believe the differentiation for beautiful discounting will come from the totality of its profile, the mechanism of action, the efficacy, the safety, the tolerability and the convenience. And given all this, we believe vidofludimus could potentially offer the best benefit-risk profile of any disease-modifying therapy.
Next slide. So where could that profile translate into commercial adoption? We see 3 particularly attractive segments that are underserved today. First, patients who prefer oral disease-modifying therapies, there's approximately 100,000 relapsing patients today currently treated with all therapies. Second, patients who need to sequence away from anti-CD20 therapies. This includes patients facing cumulative safety or tolerability concerns where patients continuing to have progression largely linked to PIRA. Over 60,000 patients fall into this bucket.
And third, the large and growing population of older relapsing MS patients, approximately 185,000 currently treated patients with relapsing disease are age 55 or older, where the benefit-risk equation can change meaningfully as patients get older, these are large clinically recognizable patient populations. And importantly, they're not mutually exclusive. And older patients sequences away from a CD20, but also prefer an oral therapy. So let's spend a minute just diving a little bit deeper to each of these respective opportunities.
Next slide, please. Starting with patients prefer oral therapies. About 25% of patients starting a treatment today will choose an oral disease modifying therapies. And as I've mentioned, about 100,000 patients are currently treated today with an oral disease-modifying therapies. And there's practical reasons why patients choose an oral. Many are looking for convenience and flexibility or simply prefer oral treatment over injections or infusions. This may include patients that have needle inversion that have busy lifestyles or have limited access to infusion centers. But despite the continued preference for oral therapies, there's still a meaningful unmet need within this class. Every currently approved oral disease modified therapy carries meaningful trade-offs across some combination of either efficacy, safety, tolerability, monitoring burden, immunosuppression or suitability for that patient, especially as they get older.
And we see some of that unmet need reflected in persistence. Approximately 30% of patients starting in oral disease-modifying therapy today will just continue the treatment and are completely off therapy within a year. So we think there's a meaningful opportunity for oral therapy that can provide effective disease control while offering a favorable safety and tolerability profile and an overall low treatment burden. If vidofludimus calcium can deliver that balance, we believe it can become attractive option within the oral disease-modifying therapy class.
Next slide. The second opportunity is sequencing away from CD20 therapies. We know that CD20s are highly effective and have transformed the treatment of MS, but not every patient can or should remain on chronic broad, B-cell depleting therapies indefinitely. As Dr. Krieger alluded to with longer anti-CD treatment -- the CD20 treatment, the immune system can become increasingly weakened over time. We know that in a real-world study of arcolizmab treated patients, about 1/3 developed low levels of IgG antibodies, and these antibodies are important to fight infection.
Consistent with that, recent data has also showed that patients treated with an anti-CD20 have a meaningfully higher risk of infection compared to patients treating on platform therapies. This cumulative immune consequences matter because patients discontinuing CD20 therapies often because reoccurring affections, low IgG levels or other safety concerns still require an effective follow-on treatment that can preserve disease control without compromising new defense. And we see a meaningful population potentially needing that next option. Our claims analysis shows approximately 18% of anti-CD20 patients switch away from the class. Another 15% will discontinue therapy completely within 1 year and approximately 15% use extended interval dosing, potentially reflecting efforts to manage infection risk and treatment burden. There is also another important consideration profound relapse suppression does not eliminate disability progression.
Approximately 20% of OCREVUS treated patients may experience PIRA within 2 to 4 years despite strong suppression of relapses. So when a patient needs to move away from an anti-CD20 therapy, whether it's because of serious infection, declining IgG levels or other safety concerns.
The question remains what comes next? And today, there is not a clear answer. And that is where we believe vidofludimus calcium could potentially play an extremely important role. As a non-immunosuppressant oral follow-on option designed to preserve disease control while reducing the new burden associated with continued B-cell depletion.
Next slide, please. The third and last opportunity I'd like to highlight are the aging relapsing MS population. Approximately 47% of patients diagnosed with a lasting MS today in the United States are aged 55 or older. This equates to about 185,000 currently treated patients. So this is not a niche population. It represents a very significant portion of the relapsing market. And as patients move into the 50s and 60s, the biology and therefore, the benefit risk discussion begins to change inflammatory activity diminishes with age, while immuno senescence infection susceptibility and comorbidities increase importantly.
For some patients that shifts the benefit with equation away from indefinite use of immunosuppressive therapies and more importantly to a medicine like vidofludimus calcium that is an immunomodulator. Older ages associated with less complete recovery from a relapse. So even if the relapses become less frequent in these older patients, the consequences of that relapse may become more significant. So this creates a real therapeutic need. How do we continue to protect older individuals living with MS from disease activity without exposing them to unnecessary levels of broad immunosuppression as they age.
And we believe that answer may be vidofludimus calcium. They could potentially offer a differentiated approach in oral. Again, that's an immunomodulator, not an immunosuppressant as an option for older, clinically stable relapsing MS patients who still require relapse protection, but whose benefit risk priorities have evolved with age.
Next slide, please. So let me close and summarize the commercial thesis. First, we are pursuing a large and growing market, $17 billion today, growing to over $25 billion by 2032. With oral disease-modifying therapies continue to represent a significant portion of the treatment class. Second, this is not a winner-take-all market. Patients will initiate therapy. They're going to switch therapies multiple times. And of course, the benefit risk evolution changes as patients dip over with age.
Third, despite more than 20 approved therapies, meaningful unmet need remains, particularly around PIRA, around disability progression around the need for safer and more tolerable agents. Fourth, treatment decisions are not solely based on efficacy. Physicians and patients make treatment decisions based upon the overall benefit risk profile of a medicine. And this is where we believe vidofludimus calcium could be differentiated. Vidofludimus will deliver strong efficacy by combining its dual Nurr1 and DHODH mechanism with oral convenience and a potentially very favorable safety and tolerability profile. We see multiple underserved large populations that we think will be very appropriate for vidofludimus calcium. This includes patients who prefer oral therapies, patients that need to sequence or switch away from the anti-CD20 class and the large and growing population of older individuals with MS.
So taken together, if we deliver a medicine and can replicate the data we've seen to date, a medicine that will have an impact on clinical relapses in medicine that will have significant impact on and the reduction of MRI regions in medicine that we think offers the best in disease safety and tolerability profile. We believe that, that medicine in vidofludimus calcium has a potential capture of meaningful sales in what is a large and growing U.S. relapsing market today. Thank you. I'll conclude with that.
Perfect. Jason. In the interest of time and the fact that these slides are available, I'm going to zip through my close so that we can take advantage of the panel and take some questions. Jessica, if you could just slip, there's a slide here on our IP. We have good IP coverage through 2044 and you can take a look at the slide later. I mean I just go to the close here. The main thesis here you've heard a lot on the science, you've heard a lot on the clinical data that we have. You've heard a lot on the unmet needs and where we think vidofludimus has the potential to fit in. I'll just close with near-term catalysts that are lapsing 2 large Phase III studies reading out at the end of the year. We're tracking to that deliverable, focused on a readout and should the data support it in NDA filing in the middle of next year. We did not talk at all about the progressive opportunity, but we will be initiating a Phase III study and progressive MS by the end of the year, and the team is really focused on that deliverable as well.
And that will lead me to put actually 2 more slides, just the the last slide, because I want to make sure -- one more, Jessica, please. I just want to make sure that everyone is aware, we will be having another one of these days on November 5, to really focus on Progressive. So Progressive is a hugely exciting and important part of the Immunic and vidofludimus calcium story. And so importantly, we thought it was worth breaking out into a separate session. So please join us on November 5 to learn more about the specifics of our plan, how we plan to design that study and the supporting evidence we have to date for that as well as the market potential. So with that, I want to flip back over to Jessica to take us through some Q&A.
Yes. Thank you, Erik, and thank you for all our speakers for these wonderful and interesting presentation.
As Erik said already, I would like to open the session now for your questions. In the interest of time, we are a little bit over already. We will prioritize the questions for our 2 experts here and take those questions first. And I actually see a lot of questions here. So I will start with Paul Matteis over Stifel, who submitted a couple of questions in writing. I know he's in transit right now. For our 2 KOLs, can the KOLs comment on how they would position video [indiscernible] versus how they think about the positioning for oral BTK drugs. Who's the right patient or patients for each. And Amit or Stephen.
I'm happy to take a first stab. It's Amit. I think Jason covered this very, very well, and I generally agree with the scope. I think that I'd make a couple of brief comments really just trying to add to that, my perspective. First, of course, we need to wait for the pivotal trial, the Phase III data in both relapsing and hopefully progressive to really know. But that said, we have high efficacy therapy for relapsing MS. We want to control relapses very, very well. That said, just controlling relapses very, very well, does not address the very important unmet needs that you've heard of. And any drug that has the capacity to limit progression and protect, I think, would be viewed as extremely exciting. You've heard that the biology starts at the very beginning. So across the whole range, if you had a sufficiently safe therapy and if relapses could also be well controlled. What strikes me as very important is the high retention, the unusually high retention with what you've seen in the open-label extension.
There are 2 reasons for people not to be retained. One is tolerability. But the other is a sense that their disease is not sufficiently well controlled, whether it's relapses or progression. So yet to be proven, but I think promising. And I would make the point that when we introduce people to a new diagnosis, I refer to it now as the new MS. One of the things that makes it the new MS, of course, is that we now should be able to control relapsing disease extremely well. But the other is that the notion of what treatment to start is not a decision as it used to be part of [indiscernible] this is for life.
And as was pointed out already, we don't need to think of any given treatment decision as retreatment that a person will be on forever. And I would make the point that the high efficacy therapy that may be increasingly the way people start to control their MS is not something that needs to be on forever and not only in the context of being on it for too long to subject people at risk later in the disease course, but that you -- after several years, 2, 3 years or so of high efficacy therapy, you may not need that to control the relapses and the therapy that has anywhere between a modest or a moderate effect of controlling relapses but has the added value of impacting progressive biology and supporting protection and repair could be introduced at that point and as a well-tolerated safe therapy for a long time thereafter. So I agree with Jason, in terms of the breadth, I would just add that additional layer to it, and we very much look forward to seeing the data emerge.
Thank you, Amit. We have another one here from -- Oh, sorry.
Stephen, I think he's going to add.
Oh, I'm sorry. I was too quick.
No, that was a wonderful answer. I would add only well, but I'm supposed to give a talk at ECTRIMS about where to use the BTK inhibitors in the current therapeutic landscape, and I haven't figured out what I'm going to say yet. So I'm working on that. But one of the challenges is the promise of the BTK agents was to accomplish in essence, what we're talking about here, but the data didn't take us there. So the data for evobrutinib didn't show superiority for relapses, the data for the GEMINI trials and tolabrunib also didn't show superiority for relapses. So the story to use for relapsed control is not there across the board and the progressive data is really mixed and so we're not talking about nonrelapsing progressive disease in this program.
That's the only thing that we have a successful trial for tolebrutinib and and that didn't garner approval here. So I think that if anything, the complexity of the data, particularly the safety data with the BTK inhibitors, doesn't get in the way of the the benefit analysis that you've heard here today for one.
Thank you, Stephen. Thank you. We have another one for our 2 experts, Actually, a similar question from 2 attendees here from [indiscernible] Life, what is the bar for a clearly positive outcome in ENSURE-1 and 2? Is it important to hit that take on EDSS? Do we need a certain effect size on plan to pursue that. And then Sam has a similar question. What do you see as a win in the upcoming Phase III RMS readout as you consider the current unmet need.
Do you want you want to kick it off?
Yes, if I can certainly give it a shot. I mean I think that I would not necessarily insist on seeing an impact on disability progression to be able to conclude that there's an important effect on targeting relapses, although, of course, one would like to see that. And especially when we're talking about a drug that might be doing more than just limiting the relapse associated worsening of disability. That said, I think as Stephen had pointed out, when we look at the totality of the data emerging from Phase III trials to date, including in progressive MS and relapsing MS and the notion that we are still struggling as a field, finding the best outcome measures to capture that, the populations, et cetera. we've come to realize that impacting the stability progression is something that we very much like to see but would not necessarily insist on saying. And I think the extent of benefit on relapsing disease activity even a moderate effect from a drug that looks to be safe and has the additional promise as vidofludimus calcium to be would be pretty compelling.
I think that's quite right. And at the end of the day, the goal is to prevent disability accumulation in all of its forms, either relapsed directly associated or there's more delayed in serious development of disability. We know that we're not targeting all the mechanisms that can accomplish that yet. And so I really would like to see a disability endpoint here, it's not the primary endpoint in the relapsing trials, they have to hit that, of course. But if we saw a disability endpoint and could point out the extent to which this mechanism attenuates disability even beyond or in the absence of relapses, that could really give us a clue as to what the long-term consequence of this strategy could be and make sure you can't see 10-year, 15-year outcomes in a 2-year trial, but you can see the change in trajectory. And that glimpse is very, very beneficial for our field.
Thank you, Stephen. Amit. I have one more for you -- or actually I have a couple of more, but I want to be mindful of your schedules. So in case you need to drop. Please feel free to drop. One more I have here is, "does success on the EDSS and RMS trial proved that a drug is beneficial on PIRA?"
Well, I'll pop in there and so that's where this determination of whether disability occurred consequent of relapses or independent of relapses helps to make that determination. The EDSS is what the regulators require we all in our field, recognize that it's a crude scale, but our regulatory agencies require it. And in that sense, it's okay because if we can achieve the endpoint on a crude scale, -- and we can also expect that we'll be able to achieve it in more nuanced ways like what I was talking about at the EDSS of 0.
So I do think that it will tell us if disability accumulation is being attenuated and I think we can then do subsequent analyses to see how much of that attenuation is attenuating PIRA, specifically, that would be helpful. Yes, I would agree with that.
I mean I think that showing an impact on disability progression and the patient population that has potentially relapsed contribution, it doesn't allow you to conclude that, that impact on disability was just because of PIRA. It could be a combination of both, but it really is something that we would want to try to dissect in terms of both clinically evident, subclinical evidence of focal intimate disease, which is the relapsed biology. So obviously, impacting disability would be great in any context, including in a relapsing trial, but how much of that would reflect non-relapsing biology is a separate question.
I would simply add to that that this will be the -- to Amit's point, the ENSURE readouts will be the next big piece of evidence in a learning journey that will continue around this question. I don't think we'll have a definitive answer out of this regardless of the magnitude of the clinical effect, which is why we're committed to running a progressive MS study in a clearly progressing population with correct powering for progression-related endpoints that will yield more evidence over time. You've heard here today a bit of why we are so excited to pursue the science into the clinic around these questions. And the insurers studies will be a meaningful advance in our understanding of the clinical impact of vidofludimus calcium on progression. But it will answer all of the questions, and that's why we're prepared to sort of pursue them even further and beyond ENSURE only to.
Yes. I also see a lot of raised hands here, and I would like to start with the first live question here. Myles Minter at William Blair.
2. Question Answer
Yes, just for Dr. Krieger and Bar-Or again, to some, again, the bar for success in the ENSURE trials and sort of the magnitude of benefit you'd expect on that time to first relapse endpoint. This is against placebo and a bunch about the trials that you look at are either against INTERFERON, against Teriflunomide. If you go back to the original Teriflunomide trials, I think on that endpoint, it was about a 24% to 28% benefit over placebo. And then others are obviously looking on top of active job. Just could you kind of put a number on the risk reduction the time to first relapse that you would expect here to have a clear win for success. That's the first one.
And then secondly, just all this focus on confirmed disability worsening as a 3-month endpoint. If you saw a trend of a similar to some of the BTK inhibitor data that we're seeing, which I think is in the mid-teens percentages, if I remember. Would that be something that would get you excited?
I'll let Steve maybe take this one initially.
Yes. So I don't have a specific answer to what the bar would be for success. I really don't accept statistical significance would be awfully nice to start with. But I think you're right that the annualized absolute reduction of Teriflunomide back in its pivotal trial from the 2012 era was in that 20% to 30% range. And so I expect we could achieve that here. And in general, relapsed numbers now the raw number as close to the percent difference are much lower than they were in that year. And so we sort of look at the actual annualized relapse rate numbers. We've gotten accustomed to seeing numbers that are remarkably low. And I think we want to see something that's similarly in that range here so that we know that we're playing in the same ballpark in modern MS, new MS as Dr. Bar-Or said earlier. But I don't have a specific number that we look to. I really don't.
You asked also if there's a progressive signal akin to what we see with the BTK inhibitors in this well absent population? Would that be useful? Absolutely because that's the highest bar we kind of have now for what constitutes efficacy in the emerging therapeutic landscape. And so if we saw that here in these trials, I think that would be successful.
And I would agree completely. I think as Stephen pointed out, it's tough to try to get a number that would be sort of a fair comparison with what we have seen many years ago in the the natural history, so to speak, or at least the relapse frequency of people has changed so much over the last years. But I think an effect size that is in the range of what you might expect for Teriflunomide with the added concept that there's another biology that's critically important that is being targeted in a way that distinguishes the 2, I think, would be extremely important.
Of course, very much hope, and I think based on the Phase II, there's a very good chance of hitting those end points at a level that we would be happy with in terms of the relapsing trials, but I would can make the point that even if we had a medicine that did nothing against relapses, but is something meaningful against the unmet need protection and the support of repair, that to me would have a huge place in the MS market. I know we're not talking today in detail beyond the relapsing aspect, but that's something for us just to keep in mind, which is part of my interest in this molecule. And I think it will emerge as it has a good chance of emerging as having a benefit on the 2 different biologies of importance.
Thank you, Myles. The next one I have in the queue here is Jatin [indiscernible] at Guggenheim.
Great presentation, both physicians and the company. Just a question on the market dynamics. I think the company has done a good job sort of articulating the buckets of patients, whether these are new patients, switching patients or patients who are not treated or patients who are on CD20. So the question for both the physicians is that, look, I think when this therapy becomes available, you're also going to have remibrutinib right, because that gives maybe a little bit of a different type of a BTK inhibitor. How would you adopt redo in each of these buckets of patients that the company highlights.
If you can just talk about a little bit the market adoption that will be helpful, assuming that the study meets the bar that you sort of all have in your mind?
Well, I can start here and say that the safety profile for the BTK inhibitors as a class. And I sort of question whether we should think of them as a class. The safety margins have not been very reassuring. So of course, tolebrutinib's principal safety issue has been deliver concern, which limited its FDA approval. With fenebrutinib, there is just a real significant imbalance in mortalities and fatalities that we don't yet fully understand. And I don't know what the regulators will do with it. And Remy, of course, we've all seen the same top line stuff, but I haven't seen anything beyond that yet to really dig into the safety and, of course, the efficacy.
So when we think about post B-cells of [indiscernible] patients where we're trying to emphasize safe transitions and a safer modulation of the immune system. I'm not sure yet what we've seen with the BTK inhibitors for which we have data serves that purpose. When we talk about the aging population, where, again, we're trying to be gentler to the immune system and target perhaps progressive mechanisms. I'm not sure we've seen that yet with the exception of perhaps the tolebrutinib as PMS data, but the FDA hasn't brought that to market here.
So there are real pressures against the use case that you're hearing about for Vido in terms of safety and the aging population. So I still think that this role this mechanism has a real role in those buckets in ways that I'm not convinced that the BTK inhibitors are best aligned for.
And I add that especially sort of the longer-term lens in the sense that I personally hope I'm sure Stephen as well and others that we will see at least 1 or 2 BTK come to the market. But that said, I think that with BTK is over time, we're going to see more and more individuals running into trouble in terms of immune response difference. There's still an impact on the immune system that is not that subtle. And it's again one of those things where we have very limited experience in terms of long-term exposure. And I suspect that the profile of vidofludimus calcium is one that will be tolerated in more people over a more extended period of time.
If I could just add on this 1 really briefly. I mean I think the themes you've heard throughout this talk from all of our presentations today is that is a highly heterogeneous disease, chronic treatment, more treatment options are needed and different types of mechanistic approaches are needed. So I would say as someone who cares a lot about MS and MS drug development, we welcome the success of BTKIs. And the sort of underlying crust of the question, I would suggest that: a, first on remibrutinib, specifically, we need to wait and see data. Right now, we have a top line press release, no details. So it's a little bit premature. We don't have our own Phase III data even read out yet. It's a little bit premature to talk about positioning.
What I'm highly confident in is that both approaches are needed and both approaches have space, and both approaches can create value for people living with the disease. That is undoubtedly true. And I, for one, very much look forward to seeing their data in Toronto in a few weeks, and we'll have more to say about it after we've seen the results.
We now have lost Jatin. I will just continue with the next question that came in and writing here for Dr. Bar-Or and/or Krieger. Does Dr. Bar-Or and Krieger feel that we will have or do have good measures of progression versus relapse for regular clinical practice decision-making?
Yes. That's -- I think the simple answer is we are not where we would like to be. We are increasingly recognizing that there are much more subtle ways in which people can get worse that we are not able to pick up with a typical follow-up, alterative efforts to try to get more sensitive measures, more accurate measures that can in an individual over time in form. And of course, the whole aspect of biomarkers that ideally would capture what's happening under the surface because we think the biology is eating away at the reserve when that reserve is not treated to be protected. So it's not a matter of having a more sensitive clinical measure. It's a matter of recognizing and being able to identify what's under the surface. So as of today, we know we need to do better and people are working hard including our groups and trying to be able to establish some additional measures. There's some early traction with some of the fluid biomarkers. But of course, as you know, still looking for ones that are particularly informing on the non-relapsing progressive biology and injury under the surface.
[indiscernible] I concur it completely. I could not think that's perfect.
Thank you, both. The next one in the queue here, I see is Marc Goodman over at Leerink.
Yes. question for the physicians, is what percent of the patients have you switched from anti-CD20 therapies already basically? And what agent are you switching to today?
Steve, why do you start and I fully agree with you.
Okay. Perfect. Well, listen, part of my strategy is informed by your trial looking to see whether we can we felt the leaders only briefly and then stop it after a shorter period of time. So you're actually moving that field that faster of our field forward. So this is, as you heard, with the heterogeneity of the disease, there's not a one-size-fits-all answer to this. So certainly, when somebody reaches age 60, for instance, I'm not taking all of them off of B cells a cheater but we are having mitigating strategies. So either extended interval dosing as a bridge to having people come off of a B-cell depleter, sometimes treating 2 B-cell reconstitution. So rather than doing it at any fixed time scale waiting for B cells to come back, which for older patients can sometimes be quite prolonged. And then the third group is those that you take off altogether.
I'm -- at this point, I'll be honest, being somewhat reactive still. I take people off of a B-cell depleter when it is starting to cause things that I don't like. What I haven't yet adopted in my own practice is a proactive taking people off of the B cell depleters because I don't think we can perfectly risk stratify who is vulnerable to infections and other consequences. That's where that hypogammaglobulinemia data that I showed is starting to be more and more instructive for our field.
So that -- I put that in there because I think that's where our field is going. Looking for biomarkers of risk, not just biomarkers of benefit to help determine who and when to take people off these agents. But what I did say in my presentation is I'm telling people now this is a 5- to 10-year plan. And so I don't imagine we're going to keep a lot of people on B-cell depletion for more than 10 years moving forward. Maybe that prediction is wrong. So I think it's more of a duration of therapy rather than a particular age but we'll see if that prediction is borne out. Dr. Bar-Or, do you have additional thoughts on that?
As anticipated, I agree completely, Stephen. I think the study that you're alluding to that we're pursuing is an early in the course of MS randomized discontinuation trial from anti-CD20. That is based on the biological insight that if you allow these cells to come back, they come back differently and in ways that 1 thing is relevant are relevant to disease activity, although it's very clear that not everybody will have sustained durable remission from relapsing disease after the discontinuation. But some probably will. And for us, it's an opportunity to understand the biology of who's different and why and whether that could be predicted from early samples.
So it's really a biologically based hypothesis that we hope to learn a lot about in terms of MS mechanisms and beyond. But I think that the notion of people coming off high efficacy therapy is being entertained across quite a broad age range, still, in particular, in people who get older or as Stephen said, in anybody who regardless of age, is having problems. And by the way, numerically, more people who run a serious infection, even with their immunoglobulin is perfectly fine than those who -- the relatively low frequency will go very low and have an increased risk of serious infections. And so we stay vigilant throughout the course regardless of the duration of treatment, but increasingly vigilant with increased exposure and age. And there is no single treatment switch that we would consider it consider a variety of treatments. It's almost like thinking a person coming in new, and what might you consider that would be sufficient to control there in MS.
Thanks for adding that. I didn't mention that. It really depends on what they're on before and then what we're going to start them on. So it's a fresh discussion. That's a good point.
Great. I know we have a ton of more questions here, both in writing, and I also see a lot of raised hands. Unfortunately, we are well over time here. So we would like to close the webcast for today. If you have more questions, we are more than happy to address this one-on-one. We are also happy to forward any questions to our 2 experts here and get back to you guys. So please feel free to reach out to me after the webcast. And I will hand it back over to Erik to wrap it up and to summarize today.
I'm not sure I can summarize. It's been such a full session, but I really just want to first, say thank you, especially to Dr. Krieger and Dr. Bar-Or, for your expertise, your passion, your care for patients and lending your voices to our science -- our session in advancing the science behind vido as well as MS care more broadly, just so value your collaborations and participation today. So thank you very much.
Thank you as well, of course, to my colleagues for all the hard work going into today, but more importantly, the hard work you do every day to advance vidofludimus calcium in the clinic. And for all the folks on the line for your interest and your time is a huge time investment, there's a lot of things you can be doing with your time. We really, really appreciate your interest in learning more about vidofludimus calcium and Immunic. And as I said in the very beginning, this is an unbelievably exciting time for us as we prepare to read these studies out at the end of the year. We continue to be on track for that. as we continue to prepare beyond these studies with a progressive MS pivotal trial in the works coming and as Jessica said, we are very committed to addressing any questions that were left on the answer here today. We'll find the right venues to do that. We thank you for your engagement. Please you come back and join us on November 5. I'm sure if you have a lot of questions about RMS, you'll have even more about Progressive MS and because we are thrilled and excited to bring vidofludimus calcium into that arena as well.
So with that, I'll close the session again and just say thank you again to everyone for participating in the great session, and we look forward to engaging with you all at various forms in the very near future. Thanks, everyone.
Thank you, Erik. This concludes our event today. Thank you so much for joining. The webinar has now concluded. You may now disconnect. Bye-bye.
Thank you. Bye-bye.
Bye.
Immunic, Inc. — Special Call - Immunic, Inc.
Financial data from Immunic, Inc.
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Jun '26 |
+/-
%
|
||
| Revenue | - - |
-
100%
|
|
| - Direct Costs | - - |
-
-
|
|
| Gross Profit | - - |
-
-
|
|
| - Selling and Administrative Expenses | 27 27 |
41%
41%
-
|
|
| - Research and Development Expense | 91 91 |
6%
6%
-
|
|
| EBITDA | -118 -118 |
12%
12%
-
|
|
| - Depreciation and Amortization | 0.15 0.15 |
6%
6%
-
|
|
| EBIT (Operating Income) EBIT | -118 -118 |
12%
12%
-
|
|
| Net Profit | -112 -112 |
10%
10%
-
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunic, Inc. Stock News
Company Profile
Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
StocksGuide Premium
| Head office | United States |
| CEO | Dr. Vitt |
| Employees | 92 |
| Founded | 2003 |
| Website | imux.com |


